Mosaic ImmunoEngineering Inc. - Quarter Report: 2007 November (Form 10-Q)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C.
20549
FORM
10-Q
(Mark
One)
x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For
the
quarterly period ended November 30, 2007
OR
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For
the
transition period from ___________ to _______________
Commission
File Number 0-22182
PATRIOT
SCIENTIFIC
CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of
incorporation
or organization)
|
84-1070278
(I.R.S.
Employer Identification No.)
|
6183
Paseo Del Norte, Suite 180, Carlsbad, California
(Address
of principal executive offices)
|
92011
(Zip
Code)
|
(Issuer’s
telephone number): (760) 547-2700
Indicate
by check mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. YES x NO o
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of
“accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange
Act. (Check one):
Large
accelerated filer o Accelerated
filer x Non-accelerated
filer o
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
Yes o No
x
On
January 4, 2008, 391,472,101 shares of common stock, par value $.00001 per
share
(the issuer’s only class of voting stock) were outstanding.
INDEX
Page
|
|
PART
I. FINANCIAL
INFORMATION
|
|
ITEM
1. Financial Statements
|
|
Condensed
consolidated Balance Sheets as of November 30, 2007 (unaudited) and
May
31, 2007
|
3
|
Condensed
consolidated Statements of Operations for the three and six months
ended
November 30, 2007 and 2006 (unaudited)
|
4
|
Condensed
consolidated Statements of Cash Flows for the six months ended November
30, 2007 and 2006 (unaudited)
|
5
|
Notes
to Condensed consolidated Financial Statements (unaudited)
|
6-21
|
ITEM
2. Management’s Discussion and Analysis of Financial Condition and Results
of Operations
|
22-32
|
ITEM
3. Quantitative and Qualitative Disclosures About Market
Risk
|
32
|
ITEM
4. Controls and Procedures
|
32
|
PART
II. OTHER
INFORMATION
|
|
ITEM
1. Legal Proceedings
|
33
|
ITEM
1A. Risk Factors
|
33
|
ITEM
2. Unregistered Sales of Equity Securities and Use of
Proceeds
|
33
|
ITEM
3. Defaults Upon Senior Securities
|
33
|
ITEM
4. Submission of Matters to a Vote of Security Holders
|
34
|
ITEM
5. Other Information
|
34
|
ITEM
6. Exhibits
|
34-36
|
SIGNATURES
|
|
2
Patriot
Scientific
Corporation
Condensed
Consolidated Balance
Sheets
November
30,
2007
|
May
31,
2007
|
|||||||
ASSETS
|
(Unaudited)
|
|||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ |
7,576,343
|
$ |
21,605,428
|
||||
Restricted
cash and cash equivalents
|
50,487
|
102,346
|
||||||
Marketable
securities and short term investments
|
12,629,946
|
4,349,314
|
||||||
Accounts
receivable
|
421,050
|
352,390
|
||||||
Receivable
from affiliated company
|
210,584
|
-
|
||||||
Note
receivable
|
50,000
|
-
|
||||||
Inventory
|
312,514
|
46,361
|
||||||
Prepaid
income taxes
|
-
|
2,070,981
|
||||||
Deferred
tax assets
|
1,051,653
|
2,439,975
|
||||||
Prepaid
expenses and other current assets
|
256,135
|
431,840
|
||||||
Total
current assets
|
22,558,712
|
31,398,635
|
||||||
Property
and equipment,
net
|
80,374
|
85,518
|
||||||
Other
assets,
net
|
8,190
|
8,190
|
||||||
Investment
in affiliated
company
|
-
|
2,883,969
|
||||||
Patents
and trademarks,
net of accumulated amortization of $613,246 and $607,657
|
32,728
|
38,317
|
||||||
$ |
22,680,004
|
$ |
34,414,629
|
|||||
LIABILITIES
AND STOCKHOLDERS’
EQUITY
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable
|
$ |
455,141
|
$ |
934,298
|
||||
Accrued
expenses and other
|
213,518
|
1,086,496
|
||||||
Income
taxes payable
|
5,446,572
|
-
|
||||||
Total
current liabilities
|
6,115,231
|
2,020,794
|
||||||
Distributions
in excess
of investment in affiliated company
|
568,605
|
-
|
||||||
Deferred
tax
liabilities
|
736,259
|
12,222,944
|
||||||
Total
liabilities
|
7,420,095
|
14,243,738
|
||||||
Commitments
and
contingencies
|
||||||||
Minority
Interest
|
-
|
-
|
||||||
Stockholders’
equity:
|
||||||||
Preferred
stock, $0.00001 par value; 5,000,000 shares authorized: none
outstanding
|
-
|
-
|
||||||
Common
stock, $0.00001 par value: 500,000,000 shares authorized: 410,638,449
shares issued and 391,472,101 shares outstanding at November 30,
2007 and
406,668,661 shares issued and 393,201,134 shares outstanding at May
31,
2007
|
4,106
|
4,066
|
||||||
Additional
paid-in capital
|
69,828,330
|
72,150,581
|
||||||
Accumulated
deficit
|
(42,697,528 | ) | (43,151,678 | ) | ||||
Common
stock held in treasury, at cost – 19,166,348 shares and 13,467,527 shares
at November 30, 2007 and May 31,
2007, respectively
|
(11,874,999 | ) | (8,832,078 | ) | ||||
Total
stockholders’ equity
|
15,259,909
|
20,170,891
|
||||||
$ |
22,680,004
|
$ |
34,414,629
|
|
See
accompanying notes to
unaudited condensed consolidated financial
statements.
|
3
Patriot
Scientific
Corporation
Condensed
Consolidated Statements of
Operations
(Unaudited)
Three
Months Ended
|
Six
Months Ended
|
|||||||||||||||
November
30, 2007
|
November
30, 2006
|
November
30, 2007
|
November
30, 2006
|
|||||||||||||
Revenues:
|
||||||||||||||||
Product
sales and other
|
$ |
945,830
|
$ |
18,500
|
$ |
1,467,199
|
$ |
44,875
|
||||||||
Cost
of sales
|
356,338
|
-
|
507,873
|
-
|
||||||||||||
Gross
profit
|
589,492
|
18,500
|
959,326
|
44,875
|
||||||||||||
Operating
expenses:
|
||||||||||||||||
Selling,
general and administrative
|
1,986,363
|
1,736,422
|
3,944,553
|
4,468,946
|
||||||||||||
Settlement
and license expense
|
388,660
|
6,300,000
|
418,660
|
6,300,000
|
||||||||||||
Total
operating expenses
|
2,375,023
|
8,036,422
|
4,363,213
|
10,768,946
|
||||||||||||
Operating
loss
|
(1,785,531 | ) | (8,017,922 | ) | (3,403,887 | ) | (10,724,071 | ) | ||||||||
Other
income (expense):
|
||||||||||||||||
Interest
and other income
|
301,066
|
181,131
|
775,591
|
307,898
|
||||||||||||
Loss
on sale of assets
|
(924 | ) |
-
|
(1,269 | ) | (543 | ) | |||||||||
Interest
expense
|
-
|
-
|
(237 | ) |
-
|
|||||||||||
Gain
on sale of subsidiary interest
|
-
|
-
|
150,000
|
-
|
||||||||||||
Equity
in earnings of affiliated company
|
5,486,039
|
6,674,793
|
4,285,497
|
18,744,991
|
||||||||||||
Total
other income, net
|
5,786,181
|
6,855,924
|
5,209,582
|
19,052,346
|
||||||||||||
Income
(loss) before income taxes
|
4,000,650
|
(1,161,998 | ) |
1,805,695
|
8,328,275
|
|||||||||||
Provision
for income taxes
|
1,584,114
|
720,000
|
1,351,545
|
4,220,000
|
||||||||||||
Net
income (loss)
|
$ |
2,416,536
|
$ | (1,881,998 | ) | $ |
454,150
|
$ |
4,108,275
|
|||||||
Basic
income per common share
|
$ |
0.01
|
$ |
-
|
$ |
-
|
$ |
0.01
|
||||||||
Diluted
income per common share
|
$ |
0.01
|
$ |
-
|
$ |
-
|
$ |
0.01
|
||||||||
Weighted
average number of common shares outstanding-basic
|
391,245,755
|
378,817,682
|
390,848,284
|
373,800,101
|
||||||||||||
Weighted
average number of common shares outstanding-diluted
|
392,627,522
|
378,817,682
|
393,814,090
|
419,862,437
|
|
See
accompanying notes to
unaudited condensed consolidated financial
statements.
|
4
Patriot
Scientific
Corporation
Condensed
Consolidated Statements of
Cash Flows
(Unaudited)
Six
months
ended
|
||||||||
November
30,
2007
|
November
30,
2006
|
|||||||
Operating
activities:
|
||||||||
Net
income
|
$ |
454,150
|
$ |
4,108,275
|
||||
Adjustments
to reconcile net income to net cash used in operating
activities:
|
||||||||
Amortization
and depreciation
|
22,915
|
21,288
|
||||||
Expense
related to extension of expiration date of stock options
|
-
|
324
|
||||||
Non
cash compensation relating to issuance of stock options and vesting
of warrants
|
346,134
|
1,773,102
|
||||||
Accrued
interest income added to investments
|
(641 | ) | (1,258 | ) | ||||
Equity
in earnings of affiliated company
|
(4,285,497 | ) | (18,744,991 | ) | ||||
Loss
on sale of assets
|
1,269
|
543
|
||||||
Value
of stock issued in connection with legal settlement
|
100,000
|
-
|
||||||
Deferred
income taxes
|
(10,098,363 | ) |
-
|
|||||
Gain
on VIE sale of portion of subsidiary interest
|
(150,000 | ) |
-
|
|||||
Reversal
of tax effect of exercise of options
|
(25,645 | ) |
-
|
|||||
Changes
in operating assets and liabilities:
|
||||||||
Accounts
receivable
|
(279,244 | ) | (3,325 | ) | ||||
Inventory
|
(266,153 | ) |
-
|
|||||
Prepaid
and other assets
|
179,695
|
172,921
|
||||||
Prepaid
income taxes
|
2,070,981
|
-
|
||||||
Accounts
payable and accrued expenses
|
(1,352,136 | ) | (390,512 | ) | ||||
Accrued
contested fee payable
|
-
|
5,960,000
|
||||||
Income
taxes payable
|
5,446,572
|
4,154,600
|
||||||
Net
cash used in operating activities
|
(7,835,963 | ) | (2,949,033 | ) | ||||
Investing
activities:
|
||||||||
Proceeds
from sales of short-term investments
|
6,800,159
|
4,024,395
|
||||||
Purchases
of short-term investments
|
(15,080,791 | ) | (4,158,346 | ) | ||||
Proceeds
from sale of restricted investments
|
52,500
|
-
|
||||||
Purchases
of property and equipment
|
(17,566 | ) | (5,947 | ) | ||||
Proceeds
from sale of property and equipment
|
125
|
-
|
||||||
Proceeds
from VIE sale of portion of subsidiary interest
|
100,000
|
-
|
||||||
Investment
in debt securities
|
-
|
(350,000 | ) | |||||
Distributions
from affiliated company
|
7,738,072
|
15,099,267
|
||||||
Net
cash provided by (used in) investing activities
|
(407,501 | ) |
14,609,369
|
|||||
Financing
activities:
|
||||||||
Proceeds
from exercise of common stock warrants and options
|
18,200
|
97,850
|
||||||
Repurchase
of warrants
|
(2,760,900 | ) |
-
|
|||||
Repurchase
of common stock for treasury
|
(3,042,921 | ) | (4,024,395 | ) | ||||
Net
cash used in financing activities
|
(5,785,621 | ) | (3,926,545 | ) | ||||
Net
increase (decrease) in cash
and cash equivalents
|
(14,029,085 | ) |
7,733,791
|
|||||
Cash
and cash equivalents,
beginning of period
|
21,605,428
|
3,984,240
|
||||||
Cash
and cash equivalents, end
of period
|
$ |
7,576,343
|
$ |
11,718,031
|
||||
Supplemental
Disclosure of Cash
Flow Information:
|
||||||||
Cash
payments for interest
|
$ |
237
|
$ |
-
|
||||
Cash
payments for income taxes
|
$ |
3,958,000
|
$ |
65,400
|
||||
Supplemental
Disclosure
of Non-Cash Investing and Financing
Activities:
|
||||||||
Cashless
exercise of warrants
|
$ |
25
|
$ |
225
|
||||
Cashless
exercise of stock options
|
$ |
10
|
$ |
-
|
||||
Note
receivable issued in connection with VIE sale of portion of subsidiary
interest
|
$ |
50,000
|
$ |
-
|
|
See
accompanying notes to
unaudited condensed consolidated financial
statements.
|
5
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
1. Basis
of Presentation
and Summary of Significant Accounting Policies
The
unaudited condensed consolidated financial statements of Patriot Scientific
Corporation (the “Company”, “we”, “us” or “our”) presented herein have been
prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”)
for quarterly reports on Form 10-Q and do not include all of the information
and
footnotes required by accounting principles generally accepted in the United
States of America. These financial statements should be read in conjunction
with
our audited consolidated financial statements and notes thereto included in
our
Report on Form 10-K for our fiscal year ended May 31, 2007.
In
the
opinion of management, the interim condensed consolidated financial statements
reflect all adjustments of a normal recurring nature necessary for a fair
presentation of the results for the interim periods
presented. Operating results for the six month period ended November
30, 2007 are not necessarily indicative of the results that may be expected
for
the year ending May 31, 2008.
Basis
of
Consolidation
The
condensed consolidated statement of operations for the three and six months
ended November 30, 2006 includes our accounts and those of our majority owned
subsidiaries, Metacomp, Inc. and Plasma Scientific Corporation. The condensed
consolidated balance sheet at May 31, 2007 and the condensed consolidated
financial statements as of and for the three and six months ended November
30,
2007 include our accounts, those of our majority owned subsidiaries that are
not
considered variable interest entities (“VIE”s) and all VIEs for which we are the
primary beneficiary. All significant intercompany accounts and transactions
have
been eliminated.
Consolidation
of
Affiliate
In
January 2003, the Financial Accounting Standards Board (“FASB”) issued FASB
Interpretation 46, Consolidation of Variable
Interest
Entities, an Interpretation of ARB No. 51 (“FIN 46”). In December 2003,
the FASB modified FIN 46. FIN 46 provides a new framework for identifying VIEs
and determining when a company should include the assets, liabilities,
noncontrolling interests and results of activities of a VIE in its consolidated
financial statements.
A
VIE is
a corporation, partnership, limited liability corporation, trust or any other
legal structure used to conduct activities or hold assets that either (1) has
an
insufficient amount of equity to carry out its principal activities without
additional subordinated financial support, (2) has a group of equity owners
that
are unable to make significant decisions about its activities, or (3) has a
group of equity owners that do not have the obligation to absorb losses or
the
right to receive returns generated by its operations.
FIN
46
requires a VIE to be consolidated if a party with an ownership, contractual
or
other financial interest in the VIE is obligated to absorb a majority of the
risk of loss from the VIE’s activities, is entitled to receive a majority of the
VIE’s residual returns (if no party absorbs a majority of the VIE’s losses), or
both. A variable interest holder that consolidates the VIE is called the primary
beneficiary. Upon consolidation, the primary beneficiary generally must
initially record all of the VIE’s assets, liabilities, and noncontrolling
interests at fair value and subsequently account for the VIE as if it were
consolidated based on majority voting interest.
FIN
46
was effective immediately for VIEs created after January 31, 2003. The
provisions of FIN 46, as revised, were adopted as of December 31, 2003, for
our
interests in all VIEs. Beginning with the quarter ended May 31, 2007, we
consolidated Scripps Secured Data, Inc. (“SSDI”) as SSDI was deemed a VIE and we
determined that we were the primary beneficiary of SSDI.
Investment
in Affiliated
Company
We
have a
50% interest in Phoenix Digital Solutions, LLC (see Note 5). This investment
is
accounted for using the equity method of accounting since the investment
provides us the ability to exercise significant influence, but not control,
over
the investee. Significant influence is generally deemed to exist if we have
an
ownership interest in the voting stock of the investee of between 20% and 50%,
although other factors, such as
representation on the investee’s board of directors, are considered in
determining whether the equity method of accounting is appropriate. Under the
equity method of accounting, the investment, originally recorded at cost, is
adjusted to recognize our share of net earnings or losses of the investee and
is
recognized in the consolidated statements of operations in the caption “Equity
in earnings (loss) of affiliated company”.
6
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Investment
in Affiliated Company,
continued
We
review
our investment in affiliated company to determine whether events or changes
in
circumstances indicate that its carrying amount may not be recoverable. The
primary factors we consider in our determination are the financial condition,
operating performance and near term prospects of the investee. If the decline
in
value is deemed to be other than temporary, we would recognize an impairment
loss.
Revenue
Recognition
We
recognize revenue from the sale of our product upon shipment to the customer,
at
which time title transfers and we have no further obligations. Fees for
maintenance or support are recorded on a straight-line basis over the underlying
period of performance. Revenue from technology license agreements is recognized
at the time we enter into a contract and provide the customer with the licensed
technology. At this point, we have performed all of our obligations under
contract, the rights to our technology have been transferred and no significant
performance obligations remain.
SSDI
recognizes revenue upon shipment of its product and recognizes revenue on its
short-term installation contracts as time and materials costs are
incurred.
SSDI
maintains an agreement with a distributor which accounts for the majority of
SSDI’s product sales. This agreement provides for a limited product warranty for
a period of one year from the date of sale to the end user. The warranty does
not cover damage to the product after it has been delivered to the distributor.
SSDI’s agreement with the distributor also allows the distributor the right to
stock rotation whereby the distributor, on a six month basis, may return product
for replacement products of the distributor’s choosing provided that the
aggregate price of the replacement products is equal to the price of the
original products returned. Such stock rotations shall not exceed 10% of the
distributor’s purchases from SSDI in the prior twelve month period for any year
and any single rotation shall not exceed 6% of the total rotational allowance
for that year. The first stock rotation shall not occur before February
2008.
Shipping
and
Handling
Emerging
Issues Task Force (“EITF”) Issue No. 00-10, Accounting for Shipping
and Handling
Fees and Costs, requires shipping
and
handling fees billed to customers to be classified as revenue and shipping
and
handling costs to be classified as either cost of sales or disclosed in the
notes to the financial statements. SSDI includes shipping and handling fees
billed to customers in net sales. Shipping and handling costs associated with
inbound freight are included in cost of sales.
Net
Income (Loss) Per
Share
We
apply
Statement of Financial Accounting Standards (“SFAS”) No. 128, Earnings Per Share, for the
calculation of "Basic" and "Diluted" earnings per share. Basic earnings per
share includes no dilution and is computed by dividing income available to
common stockholders by the weighted average number of common shares outstanding
for the period. Diluted earnings per share reflects the potential dilution
of
securities that could share in the earnings of an entity. For the
three months and six months ended November 30, 2007, 5,495,000 potentially
dilutive common shares related to our outstanding warrants and options were
not
included in the calculation of diluted income per share as they had an
anti-dilutive effect. For the three months ended November 30, 2006,
40,690,194 potentially dilutive common shares related to our outstanding
warrants and options were not included in the calculation of diluted loss per
share as they had an anti-dilutive effect. For the six months ended November
30,
2006, 100,000 potentially dilutive common shares related to our outstanding
warrants and options were not included in the calculation of diluted income
per
share as they had an anti-dilutive effect.
7
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Net
Income (Loss) Per Share,
continued
Three
Months Ended November 30,
2007
|
||||||||||||
Numerator
(Income)
|
Denominator
(Shares)
|
Per
Share Amount
|
||||||||||
Basic
EPS:
|
||||||||||||
Net
income
|
$ |
2,416,536
|
391,245,755
|
$ |
0.01
|
|||||||
Diluted
EPS:
|
||||||||||||
Effect
of dilutive securities:
|
||||||||||||
Options
and
warrants
|
-
|
1,381,767
|
||||||||||
Income
available to common shareholders
|
$ |
2,416,536
|
392,627,522
|
$ |
0.01
|
Three
Months Ended November 30,
2006
|
|||||||||||||
Numerator
(Loss)
|
Denominator
(Shares)
|
Per
Share Amount
|
|||||||||||
Basic
EPS:
|
|||||||||||||
Net
loss
|
$ | (1,881,998 | ) |
378,817,682
|
$ |
-
|
|||||||
Diluted
EPS:
|
|||||||||||||
Effect
of dilutive securities:
|
|||||||||||||
Options
and
warrants
|
-
|
-
|
|||||||||||
Loss
available to common shareholders
|
$ | (1,881,998 | ) |
378,817,682
|
$ |
-
|
|||||||
Six
Months Ended November 30,
2007
|
|||||||||||||
Numerator
(Income)
|
Denominator
(Shares)
|
Per
Share Amount
|
|||||||||||
Basic
EPS:
|
|||||||||||||
Net
income
|
$ |
454,150
|
390,848,284
|
$ |
-
|
||||||||
Diluted
EPS:
|
|||||||||||||
Effect
of dilutive securities:
|
|||||||||||||
Options
and
warrants
|
-
|
2,965,806
|
|||||||||||
Income
available to common shareholders
|
$ |
454,150
|
393,814,090
|
$ |
-
|
||||||||
Six
Months Ended November 30,
2006
|
|||||||||||||
Numerator
(Income)
|
Denominator
(Shares)
|
Per
Share Amount
|
|||||||||||
Basic
EPS:
|
|||||||||||||
Net
income
|
$ |
4,108,275
|
373,800,101
|
$ |
0.01
|
||||||||
Diluted
EPS:
|
|||||||||||||
Effect
of dilutive securities:
|
|||||||||||||
Options
and
warrants
|
-
|
46,062,336
|
|||||||||||
Income
available to common shareholders
|
$ |
4,108,275
|
419,862,437
|
$ |
0.01
|
8
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Minority
Interest
Minority
interest in our consolidated financial statements results from the accounting
for the acquisition of a noncontrolling interest in SSDI. Noncontrolling
interest represents a partially owned subsidiary’s income, losses, and
components of other comprehensive income which should be attributed to the
controlling and noncontrolling interests or other parties with a right or
obligation that affects the attribution of comprehensive income or loss, on
the
basis of their contractual rights or obligations, if any, otherwise, on the
basis of ownership interests.
The
noncontrolling interest in SSDI, which we are required to consolidate as we
are
the primary beneficiary, has been reduced to zero due to the initial allocation
of losses prior to the period in which we were required to consolidate. If
a
noncontrolling interest has been reduced to zero, the primary beneficiary must
absorb any losses that are in excess of the value of the noncontrolling
interest’s equity. For the period in which we are required to consolidate, March
27, 2007 through November 30, 2007 we absorbed $45,864 of SSDI’s losses as we
are the primary beneficiary. The noncontrolling interest in any future profits
will not be presented until all prior losses have been recovered.
Stock-Based
Compensation
On
June
1, 2006, we adopted the provisions of SFAS No. 123(R), Share-Based Payment, which
establishes standards for the accounting of transactions in which an entity
exchanges its equity instruments for goods or services, primarily focusing
on
accounting for transactions where an entity obtains employee services in
share-based payment transactions. SFAS No. 123(R) requires a public entity
to measure the cost of employee services received in exchange for an award
of
equity instruments, including stock options, based on the grant-date fair value
of the award and to recognize it as compensation expense over the period the
employee is required to provide service in exchange for the award, usually
the
vesting period. Stock-based awards to non-employees are accounted for using
the
fair value method in accordance with SFAS No. 123, Accounting for Stock Based
Compensation.
In
November 2005, FASB issued FASB Staff Position No. FAS 123R-3, “Transition Election Related
to
Accounting for Tax Effects of Share-Based Payment Awards” (“FAS
123R-3”). We have elected to adopt the alternative transition method
provided in FAS 123R-3. The alternative transition method includes a
simplified method to establish the beginning balance of the additional paid-in
capital pool (“APIC pool”) related to the tax effects of employee share-based
compensation, which is available to absorb tax deficiencies recognized
subsequent to the adoption of SFAS No. 123(R).
Stock-based
compensation expense recognized during the period is based on the value of
the
portion of share-based payment awards that is ultimately expected to vest during
the period. Stock-based compensation expense recognized in our condensed
consolidated statement of operations for the six months ended November 30,
2006
included compensation expense for share-based payment awards granted prior
to,
but not yet vested as of May 31, 2006 based on the grant date fair value
estimated in accordance with the pro forma provisions of SFAS No. 123 and
compensation expense for the share-based payment awards granted subsequent
to
May 31, 2006 based on the grant date fair value estimated in accordance
with the provisions of SFAS No. 123(R). Stock-based compensation expense
recognized in our condensed consolidated statement of operations for the six
months ended November 30, 2007 included compensation expense for share-based
payment awards granted subsequent to May 31, 2007 based on the grant date
fair value estimated in accordance with the provisions of SFAS No. 123(R).
As
stock-based compensation expense recognized in the condensed consolidated
statements of operations is based on awards ultimately expected to vest, it
has
been reduced for estimated forfeitures. SFAS No. 123(R) requires forfeitures
to
be estimated at the time of grant and revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates. The estimated average
forfeiture rate for the three and six months ended November 30, 2007 and
2006, of approximately 5% was based on historical forfeiture experience and
estimated future employee forfeitures. The estimated pricing term of option
grants for the three and six months ended November 30, 2007 and 2006 was five
years.
9
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Stock-Based
Compensation, continued
Summary
of Assumptions and
Activity
The
fair
value of stock-based awards to employees and directors is calculated using
the
Black-Scholes option pricing model, even though this model was developed to
estimate the fair value of freely tradable, fully transferable options without
vesting restrictions, which differ significantly from our stock options. The
Black-Scholes model also requires subjective assumptions, including future
stock
price volatility and expected time to exercise, which greatly affect the
calculated values. The expected term of options granted is derived from
historical data on employee exercises and post-vesting employment termination
behavior. The risk-free rate selected to value any particular grant is based
on
the U.S. Treasury rate that corresponds to the pricing term of the grant
effective as of the date of the grant. The expected volatility for the three
and
six months ended November 30, 2007 and 2006 is based on the historical
volatilities of our common stock. These factors could change in the
future, affecting the determination of stock-based compensation expense in
future periods.
Three
Months
Ended
|
Six
Months
Ended
|
Three
Months
Ended
|
Six
Months
Ended
|
|||||||||||||||||
November
30,
2007
(Unaudited)
|
November
30,
2007
(Unaudited)
|
November
30,
2006
(Unaudited)
|
November
30,
2006
(Unaudited)
|
|||||||||||||||||
Expected
term
|
5
|
years
|
4.4
|
years
|
5
|
years
|
5
|
years
|
||||||||||||
Expected
volatility
|
127
|
%
|
127-128
|
%
|
156
|
%
|
156
|
%
|
||||||||||||
Risk-free
interest rate
|
4.21
|
%
|
4.21
– 4.96
|
%
|
4.80
|
%
|
4.80
– 5.00
|
%
|
||||||||||||
Expected
dividends
|
2.82
|
%
|
2.82
|
%
|
-
|
-
|
Shares
|
Weighted
Average Exercise
Price
|
Weighted
Average Remaining
Contractual Term (Years)
|
Aggregate
Intrinsic
Value
|
|||||||||||||
Options
outstanding at June 1, 2007
|
7,245,000
|
$ |
0.40
|
|||||||||||||
Options
granted
|
2,975,000
|
$ |
0.47
|
|||||||||||||
Options
exercised
|
(1,107,846 | ) | $ |
0.16
|
||||||||||||
Options
forfeited
|
(1,017,154 | ) | $ |
0.16
|
||||||||||||
Options
outstanding at November 30, 2007
|
8,095,000
|
$ |
0.49
|
3.62
|
$ |
1,237,700
|
||||||||||
Options
vested and expected to vest at November 30, 2007
|
7,982,500
|
$ |
0.49
|
3.61
|
$ |
1,222,325
|
||||||||||
Options
exercisable at November 30, 2007
|
5,845,000
|
$ |
0.49
|
3.24
|
$ |
930,200
|
10
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Stock-Based
Compensation,
continued
The
weighted average grant date fair value of options granted during the six months
ended November 30, 2007 and 2006 was $0.35 and $0.99 per option, respectively.
The total intrinsic value of options exercised during the six months ended
November 30, 2007 and 2006 was $513,550 and $169,500, respectively, based on
the
differences in market prices on the dates of exercise and the option exercise
prices.
The
aggregate intrinsic value represents the differences in market price at the
close of the quarter ($0.61 per share on November 30, 2007) and the exercise
price of outstanding, in the money options (those options with exercise prices
below $0.61) on November 30, 2007.
As
of
November 30, 2007, there was approximately $662,167 of total unrecognized
compensation cost related to employee stock option compensation
arrangements. That cost is expected to be recognized on a
straight-line basis over the next 58 months.
The
following table summarizes employee stock-based compensation expense related
to
stock options under SFAS No. 123(R) for the three and six months ended November
30, 2007 and 2006, which was recorded as follows:
Three
Months
Ended
|
Six
Months
Ended
|
Three
Months
Ended
|
Six Months
Ended
|
|||||||||||||
November 30,
2007
|
November
30,
2007
|
November
30,
2006
|
November
30,
2006
|
|||||||||||||
Selling,
general and administrative expense
|
$ |
63,221
|
$ |
346,134
|
$ |
194,000
|
$ |
1,770,000
|
Recent
Accounting
Pronouncements
In
July
2006, the FASB issued Interpretation No. 48, Accounting for Uncertainty in Income
Taxes - an interpretation of FASB Statement No. 109 (“FIN 48”). This
interpretation clarifies the application of SFAS No. 109, Accounting for Income Taxes,
by defining criteria that an individual tax position must meet for any part
of
the benefit of that position to be recognized in a company’s financial
statements and also provides guidance on measurement, derecognition,
classification, interest and penalties, accounting in interim periods,
disclosure and transition. We adopted FIN 48 on June 1, 2007 and did not record
any cumulative effect adjustment to retained earnings as a result of adopting
FIN 48. Interest and penalties, if any, related to unrecognized tax
benefits are recorded in income tax expense. As of June 1, 2007, we
are subject to U.S. Federal income tax examinations for the tax years May 31,
1991 through May 31, 2007, and we are subject to state and local income tax
examinations for the tax years May 31, 1999 through May 31, 2007 due to the
carryover of net operating losses from previous years.
In
September 2006, the FASB issued SFAS No. 157, Fair Value Measurements
(“SFAS No. 157”). SFAS No. 157 defines fair value, establishes a framework
for measuring fair value in generally accepted accounting principals and expands
disclosures about fair value measurements. The statement does not require
new fair value measurements, but is applied to the extent that other accounting
pronouncements require or permit fair value measurements. The statement
emphasizes that fair value is a market-based measurement that should be
determined based on the assumptions that market participants would use in
pricing an asset or liability. Companies that have assets and liabilities
measured at fair value will be required to disclose information that enables
the
users of its financial statements to access the inputs used to develop those
measurements. The reporting entity is encouraged, but not required, to
combine the fair value information disclosed under this statement with the
fair
value information disclosed under other accounting pronouncements. SFAS
No. 157 is effective for fiscal years beginning after November 15, 2007. We
expect to adopt SFAS No. 157 on June 1, 2008.
We are currently assessing the impact the adoption of SFAS No. 157 will have
on
our consolidated financial statements.
11
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Recent
Accounting Pronouncements,
continued
In
February 2007, the FASB issued SFAS No. 159, The Fair Value Option for
Financial
Assets and Financial Liabilities (“SFAS No. 159”). SFAS No. 159 permits
entities to choose to measure at fair value many financial instruments and
certain other items that are not currently required to be measured at fair
value. The objective is to improve financial reporting by providing entities
with the opportunity to mitigate volatility in reported earnings caused by
measuring related assets and liabilities differently without having to apply
complex hedge accounting provisions. SFAS No. 159 also establishes
presentation and disclosure requirements designed to facilitate comparisons
between entities that choose different measurement attributes for similar types
of assets and liabilities. SFAS No. 159 does not affect any existing
accounting literature that requires certain assets and liabilities to be carried
at fair value. SFAS No. 159 does not establish requirements for
recognizing and measuring dividend income, interest income, or interest expense.
This Statement does not eliminate disclosure requirements included in other
accounting standards. SFAS No. 159 is effective in fiscal years
beginning after November 15, 2007. We are in the process of evaluating the
provisions of the statement, but do not anticipate that the adoption of SFAS
No.
159 will have a material impact on our consolidated financial
statements.
In
December 2007, the FASB issued SFAS No. 141(R), Business Combinations (“SFAS
No. 141(R)”). SFAS No. 141(R) requires acquiring entities in a business
combination to recognize the assets acquired and liabilities assumed in the
transaction; establishes the acquisition-date fair value as the measurement
objective for all assets acquired and liabilities assumed; and requires the
acquirer to disclose to investors the information they need to evaluate and
understand the nature and financial effect of the business combination. SFAS
No. 141(R) is effective in fiscal years beginning after December 15, 2008.
We expect to adopt SFAS No. 141(R) on June 1, 2009. We are currently
assessing the impact the adoption of SFAS No. 141(R) will have on our
consolidated financial statements.
In
December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests
in
Consolidated Financial Statements (“SFAS No. 160”). SFAS No. 160
requires entities to report noncontrolling (minority) interests in subsidiaries
as equity in the consolidated financial statements . SFAS No. 160 is
effective in fiscal years beginning after December 15, 2008. We expect to adopt
SFAS No. 160 on June 1, 2009. We are currently assessing the impact
the adoption of SFAS No. 160 will have on our consolidated financial
statements.
2.
Cash, Cash Equivalents and
Short-Term Investments
We
consider all highly liquid investments with original maturities of three months
or less to be cash equivalents.
Our
short-term investments consist of money market mutual funds and auction rate
securities and are reported at cost, which approximate fair market
value.
During
the quarter ended November 30, 2007 we had short-term investments in auction
rate securities of approximately $7.5 million. Auction
rate securities generally have long-stated maturities of 20 to 40
years. These securities have certain economic characteristics of
short-term investments due to a rate-setting mechanism and the ability to
liquidate them through a Dutch auction process that occurs on pre-determined
intervals of less than 90 days. Due to the frequent resetting of
interest rates, the carrying value of auction rate securities approximates
fair
value.
12
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
3.
Inventory
Inventory
at November 30, 2007, consisted of raw materials of $87,462 and finished goods
of $225,052.
4.
License
Agreements
In
February 2005, we entered into two separate licensing agreements with one
customer for our patent portfolio and Ignite microprocessor technology. The
aggregate amount of the two licenses was $3,050,000, of which $2,950,000 was
for
licensing fees and $100,000 was for maintenance services. Maintenance under
the
agreement is expected to be provided over a period not to exceed four years.
Maintenance revenue recognized during six months ended November 30, 2007 and
2006 was $12,500 and $12,500, respectively. The payment terms of the agreements
required aggregate payments of $300,000 at the time of execution, three
quarterly payments of $750,000 each on April 1, August 15, and November 15,
2005
and one final payment of $500,000 on February 15, 2006. The $500,000 payment
due
on February 15, 2006 was paid in March 2006. Total payments received in fiscal
2005 amounted to $1,050,000, and total payments received in fiscal 2006 amounted
to $2,000,000. The agreements also provide for the future payment of royalties
to us based on sales of product using the Ignite licensed technology. In
connection with this license agreement, we became obligated to the co-inventor
of the patent portfolio technology for $207,600 pursuant to a July 2004
agreement under which we were obligated to pay a percentage of all patent
portfolio licensing proceeds to the co-inventor. The amount due under that
license was payable in four installments of $51,900. The co-inventor of the
patent portfolio technology filed a lawsuit against us seeking damages and/or
enforcement of the July 2004 agreement. We challenged the enforceability of
the
agreement by counterclaim in that action. On February 14, 2007, a settlement
of
the litigation was finalized. Terms of the settlement required us to pay
$3,400,000 in cash on February 14, 2007 and $3,000,000 on May 1, 2007, which
amounted to approximately the debt claimed by the co-inventor to be owed to
him
under the July 2004 agreement. In addition, the settlement required us to make
a
donation of $15,000 on February 14, 2007 on behalf of Russell H. Fish III
(“Fish”) to Maasai Power and Education Project, Inc., and to pay Fish the
equivalent of 4% of 50% of the next $100 million of gross license fees as they
are collected by Phoenix Digital and as distributions are made to us, after
excluding the first $20 million collected by Phoenix Digital after December
1,
2006. Our commitment to make payments to Fish related to such future license
revenues will not exceed $2 million. During the six months ended November 30,
2007, we recorded $418,660 in settlement and license expenses relating to
royalty payments due to the Fish parties.
5.
Investment in Affiliated
Company/License Agreement
On
June
7, 2005, we entered into a Master Agreement (the “Master Agreement”) with
Technology Properties Limited Inc., a California corporation (“TPL”), and
Charles H. Moore (“Moore”), the co-inventor of certain of our technology,
pursuant to which we, TPL and Moore resolved all legal disputes between us.
Pursuant to the Master Agreement, we and TPL entered into the Limited Liability
Company Operating Agreement of Phoenix Digital (the “LLC Agreement”) into which
we and Moore contributed our rights to certain of our technologies.
We
and
TPL each own 50% of the membership interests of Phoenix Digital, and each of
us
has the right to appoint one member of the three member management committee.
The two appointees are required to select a mutually acceptable third member
of
the management committee. Pursuant to the LLC Agreement, we and TPL agreed
to
establish a working capital fund for Phoenix Digital of $4,000,000, of which
our
contribution was $2,000,000. The working capital fund increases to a maximum
of
$8,000,000 as license revenues are achieved. We and TPL are obligated to fund
future working capital requirements at the discretion of the management
committee of Phoenix Digital in order to maintain working capital of not more
than $8,000,000. Neither we nor TPL are required to contribute more than
$2,000,000 in any fiscal year. Distributable cash and allocation of profits
and
losses will be allocated to the members in the priority defined in the LLC
Agreement.
13
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Investment
in Affiliated
Company/License Agreement, continued
Phoenix
Digital has committed to pay a quarterly amount ranging between $500,000 and
$1,000,000 (based upon a percentage of the working capital fund balance of
Phoenix Digital) for supporting efforts to secure licensing agreements by the
other member on behalf of Phoenix Digital. During the six months ended November
30, 2007 and 2006, Phoenix Digital paid $1,374,000 and $1,968,000, respectively,
to TPL pursuant to this commitment.
We
are
accounting for our investment in Phoenix Digital under the equity method of
accounting, and accordingly have recorded our share of Phoenix Digital’s net
income of $4,285,497 during the six months ended November 30, 2007 and our
share
of Phoenix Digital’s net income of $18,744,991 during the six months ended
November 30, 2006 as an increase in our investment. Cash distributions of
$7,738,072 received from Phoenix Digital during the six months ended November
30, 2007 and cash distributions of $15,099,267 received from Phoenix Digital
during the six months ended November 30, 2006 have been recorded as a reduction
in our investment. During the three months ended November 30, 2007, Phoenix
Digital distributed earnings in excess of the carrying amount of our investment
of $568,605 at November 30, 2007. Such amount has been recorded as
“Distributions in Excess of Investment in Affiliated Company” due to our and
TPL’s obligation to fund the working capital of Phoenix Digital at the
discretion of Phoenix Digital’s management committee. We have recorded our share
of Phoenix Digital’s net income as “Equity in Earnings of Affiliated Company” in
the accompanying consolidated statements of operations for the six months ended
November 30, 2007 and November 30, 2006. At November 30, 2007 we have recorded
$210,584 as amounts receivable from affiliated company for reimbursement due
to
us of legal fees and related costs for the patent litigation (see Note
8).
During
the six months ended November 30, 2007, Phoenix Digital entered into licensing
agreements with third parties, pursuant to which it received aggregate proceeds
of $20,933,000. During the six months ended November 30, 2006,
Phoenix Digital entered into licensing agreements with third parties, pursuant
to which it received aggregate proceeds of $32,699,000. License
proceeds of $8,850,000 relating to an additional license agreement signed in
November 2006 were received in January 2007. Phoenix Digital had
recorded this amount as a license receivable.
The
condensed balance sheets and statements of operations of Phoenix Digital at
November 30, 2007 and 2006 and for the six months then ended are as
follows:
Condensed
Balance
Sheets
ASSETS:
|
2007
|
2006
|
||||||
Cash
|
$ |
4,629,045
|
$ |
7,731,427
|
||||
License
fees receivable
|
-
|
8,850,000
|
||||||
Prepaid
expenses
|
95,000
|
15,000
|
||||||
Total
assets
|
$ |
4,724,045
|
$ |
16,596,427
|
LIABILITIES
AND MEMBERS’ EQUITY:
Accounts
payable and accrued expenses
|
$ |
5,849,465
|
$ |
1,172,314
|
||||
Income
taxes payable
|
11,790
|
-
|
||||||
Members’
equity
|
(1,137,210 | ) |
15,424,113
|
|||||
Total
liabilities and members’ equity
|
$ |
4,724,045
|
$ |
16,596,427
|
14
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Investment
in
Affiliated Company/License Agreement, continued
Condensed
Statements of
Operations
2007
|
2006
|
|||||||
Revenues
|
$ |
20,933,000
|
$ |
41,549,000
|
||||
Operating
expenses
|
13,598,760
|
4,271,666
|
||||||
Operating
income
|
7,334,240
|
37,277,334
|
||||||
Interest
income
|
112,585
|
212,648
|
||||||
Net
income
|
$ |
7,446,825
|
$ |
37,489,982
|
6.
Consolidated Variable Interest
Entity
On
February 2, 2007, we invested an aggregate of $370,000 in SSDI for 2,100,000
shares of convertible preferred stock. This represents all of SSDI’s preferred
stock and a 46% ownership interest in SSDI, a California corporation that
manufactures products that protect information transmitted over secure networks.
The investment consisted of certain assets contributed by us to SSDI valued
at
$250,000 and cash of $120,000. The shares are convertible at our option into
shares of SSDI’s common stock on a one-to-one basis. The convertible preferred
stock entitles us to receive non-cumulative dividends at the per annum rate
of
$0.04 per share, when and if declared by the Board of Directors of SSDI. The
investment in SSDI’s convertible preferred stock also entitles us to a
liquidation preference of $0.40 per share, plus an amount equal to all declared
but unpaid dividends.
On
March
27, 2007, we entered into an 18 month revolving line of credit with SSDI for
a
maximum amount of $500,000. The line of credit matures on September 27, 2008.
If
we do not provide notice to SSDI at least 90 days prior to the maturity date,
the maturity date automatically extends 12 months. The line of credit is
collateralized by all assets presently owned or hereafter acquired by SSDI.
The
carrying value of the collateral is approximately $547,390 at November 30,
2007.
The creditors of SSDI do not have recourse to our other assets. On March 28,
2007, we advanced $150,000 under terms of the agreement, on April 16, 2007
we
advanced $100,000 under terms of the agreement and on September 4, 2007 we
advanced $100,000 under terms of the agreement.
The
line
of credit carries a floating interest rate which is defined as the prime rate
as
announced by Bank of America. At November 30, 2007, the interest rate on
the note was 7.50%; On December 11, 2007, the interest rate on the note was
7.25%. SSDI is required to make minimum monthly payments on the line consisting
of unpaid and accrued interest on the first day of the month following the
initial advance.
As
a
result of the line of credit, we have a variable interest in SSDI, a variable
interest entity, and we have determined that we are the primary beneficiary
as
we absorb more than half of the variable interest entity’s expected losses. FIN
46, requires us to consolidate SSDI as long as we are deemed to be the primary
beneficiary. The equity interests of SSDI not owned by us are reported as a
minority interest in our November 30, 2007 condensed consolidated balance
sheet. As of November 30, 2007, the noncontrolling interest in SSDI,
which we are required to consolidate as we are the primary beneficiary, has
been
reduced to zero due to the initial allocation of losses prior to the period
in
which we were required to consolidate. If a noncontrolling interest has been
reduced to zero, the primary beneficiary must absorb any losses that are in
excess of the value of the noncontrolling interest’s equity. For the period in
which we are required to consolidate, March 27, 2007 through November 30, 2007
we absorbed $45,864 of SSDI’s losses as we are the primary beneficiary. The
noncontrolling interest in any future profits will not be presented until all
prior losses have been recovered.
15
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Consolidated
Variable Interest
Entity, continued
Prior
to
initial consolidation, we recognized a $126,746 impairment loss on our
investment for the losses of SSDI for the period February 2007 through March
26,
2007.
Upon
initial consolidation of the variable interest entity, on March 27, 2007,
$251,146 of current assets, $43,199 of net property and equipment, $47,240
of
other assets, $98,331 of current liabilities and no minority interest were
included on the consolidated balance sheet.
During
the three months ended August 31, 2007, SSDI sold a membership interest in
its
subsidiary DataSecurus, LLC to an unrelated third party for $100,000
in cash and a $50,000 note receivable due June 2008.
7. Stockholders’
Equity
During
July 2006 we commenced our Board of Director approved stock buyback program
in
which we repurchase our outstanding common stock from time to time on the open
market. As part of the program we purchased 5,698,821 and 4,874,827
shares of our common stock at an aggregate cost of $3,042,921 and $4,024,395
during the six months ended November 30, 2007 and 2006,
respectively.
The
following table summarizes equity transactions during the six months ended
November 30, 2007:
Common
Stock
|
Additional
Paid-
|
Accumulated
|
Treasury
|
|||||||||||||||||
Shares
|
Amounts
|
in
Capital
|
Deficit
|
Stock
|
||||||||||||||||
Balance
June 1, 2007
|
393,201,134
|
$ |
4,066
|
$ |
72,150,581
|
$ | (43,151,678 | ) | $ | (8,832,078 | ) | |||||||||
Exercise
of warrants and options at $0.05 to $0.10 per share
|
250,000
|
3
|
18,197
|
-
|
-
|
|||||||||||||||
Cashless
exercise of options
|
982,846
|
10
|
(10 | ) |
-
|
-
|
||||||||||||||
Cashless
exercise of warrants
|
2,536,942
|
25
|
(25 | ) |
-
|
-
|
||||||||||||||
Issuance
of stock
|
200,000
|
2
|
99,998
|
-
|
-
|
|||||||||||||||
Repurchase
of warrants
|
-
|
-
|
(2,760,900 | ) |
-
|
-
|
||||||||||||||
Non-cash
compensation
|
-
|
-
|
346,134
|
-
|
-
|
|||||||||||||||
Tax
effect of exercise of options
|
-
|
-
|
(25,645 | ) |
-
|
-
|
||||||||||||||
Repurchase
of common stock for treasury
|
(5,698,821 | ) |
-
|
-
|
-
|
(3,042,921 | ) | |||||||||||||
Net
income
|
-
|
-
|
-
|
454,150
|
-
|
|||||||||||||||
Balance
November 30, 2007
|
391,472,101
|
$ |
4,106
|
$ |
69,828,330
|
$ | (42,697,528 | ) | $ | (11,874,999 | ) |
During November 2007 we issued 200,000 shares of our common stock to a former officer in connection with a settlement agreement (see Note 8).
Stock
Options
and Warrant
Activity
As
of
November 30, 2007, we had 100,000 options outstanding pursuant to our 1996
Stock
Option Plan exercisable at $0.07 per share expiring in 2009; 775,000 options
outstanding pursuant to our 2001 Stock Option Plan exercisable at a range of
$0.07 to $0.86 per share expiring through 2012; 3,350,000 options outstanding
pursuant to our 2003 Stock Option Plan exercisable at a range of $0.05 to $0.49
per share expiring through 2012; and 3,870,000 options outstanding pursuant
to
our 2006 Stock Option Plan exercisable at a range of $0.45 to $0.70 per share
expiring through 2012. Some of the options outstanding under these
plans are not presently exercisable and are subject to meeting vesting
criteria.
During
the quarter ended November 30, 2007, we issued options to acquire 750,000 shares
of common stock to our newly appointed chief financial officer at an exercise
price of $0.45 per share.
16
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Stockholders’
Equity,
continued
During
the six months ended November 30, 2007, directors exercised stock options to
purchase 125,000 shares of common stock for proceeds of $11,950, and a director
exercised stock options utilizing a share certification exchange procedure
within our stock option plans to exercise 1,500,000 shares and receive 982,846
new shares upon exercise.
During
the six months ended November 30, 2007, we recorded $346,134 of non cash
compensation expense related to stock options issued and vesting of stock
options.
As
of
November 30, 2007, we had warrants outstanding to purchase 500,000 common shares
at exercise prices ranging from $0.06 to $1.00 per share, expiring at various
dates through 2011. During the six months ended November 30, 2007, we
issued no warrants to purchase shares of common stock, an investor exercised
warrants to purchase 125,000 shares of common stock for proceeds of $6,250,
1,898,973 warrants expired, 3,500,000 warrants were exercised utilizing the
cashless method of exercise for 2,536,942 shares, and we repurchased 7,000,000
warrants for $2,760,900 under terms of our warrant repurchase agreement as
detailed below.
In
connection with a previous debt agreement, the Company entered into an
Antidilution Agreement (the “Antidilution Agreement”) with Swartz Private
Equity, LLC (“Swartz”) wherein the Company was obligated to issue to Swartz
warrants equal to 11% of the common stock issued between January 28, 2002 and
March 11, 2002, 20% of the common stock issued between March 12, 2002 and April
1, 2003, and after April 1, 2003, 30% of the common stock issued to any parties
other than Swartz. There were no warrants issued during the three
month period ended August 31, 2006 in connection with the Antidilution
agreement, nor were warrants issued during September 2006 in connection with
the
Antidilution agreement. On October 10, 2006, the Company entered into an
Approval Rights Agreement and Termination of Antidilution Agreement and Addendum
to Warrants (the “Termination Agreement”) with Swartz to terminate the
Antidilution Agreement. In consideration for entering into the
Termination Agreement, the Company agreed that through May 31, 2008 it would
obtain Swartz’s written approval at least 30 days prior to entering into (i) any
acquisition of any business entity or asset of any kind where the aggregate
number of shares of common stock and derivative securities (on a fully diluted
basis) issued as consideration for the acquisition equals or exceeds 10% of
the
number of shares of common stock of the Company outstanding at the time of
the
acquisition (on a fully diluted basis) or (ii) any acquisition (regardless
of
size) by the Company of any business entity or asset of any kind that is not
unanimously approved by the Company’s board of directors.
On
July
19, 2007, we entered into a warrant redemption agreement with Lincoln Ventures,
LLC, whereby at our option, we agreed to redeem certain warrants representing
the right to acquire an aggregate of up to 7,000,000 shares of our common stock,
through October 2007. The warrants were redeemable in quantities not to exceed
2,000,000 warrants in the first two calendar months and 3,000,000 in the last
calendar month, at a price equal to the product of (a) the volume weighted
average of the daily volume weighted average prices of our common stock for
all
trading days in the applicable calendar month, minus the exercise price of
the
warrant, multiplied by (b) the number of shares being redeemed from that
warrant. Lincoln Ventures, LLC was prohibited from exercising any of the
warrants as long as we remained in compliance with the agreement. Additionally,
Lincoln Ventures, LLC was prohibited from purchasing any shares of our common
stock on the open market during any “pricing month” defined in the agreement as
the calendar month immediately preceding the calendar month in which we deliver
the redemption notice to Lincoln Ventures, LLC. As of November 30,
2007, we repurchased all of the additional warrants pursuant to the
agreement.
17
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
8. Commitments
and
Contingencies
Litigation
Lowell
Giffhorn
Arbitration
On
September 23, 2005, Lowell Giffhorn, a former executive officer
and a former director of the Company, submitted a demand for arbitration with
the American Arbitration Association related to the termination of
Mr. Giffhorn's employment with the Company. Mr. Giffhorn asserted that
the termination of his employment with the Company was unlawful, retaliatory,
wrongful, violated public policy, violated the covenant of good faith and fair
dealing and violated securities laws. Mr. Giffhorn sought damages of
approximately $4,500,000 (excluding claims for punitive damages and attorney’s
fees). On November 1, 2007, the Company and Mr. Giffhorn reached a settlement
where Mr. Giffhorn was given $500,000 and 200,000 shares of restricted Company
stock in exchange for a comprehensive release of all claims against the
Company. We have recorded these costs in selling, general and
administrative expenses for the three and six months ended November 30,
2007.
Patent
Litigation
Pursuant
to the joint venture that the Company entered into in June 2005 with TPL (in
settlement of inventorship/ownership litigation between the parties, and in
return for a 50-50 sharing of net licensing and enforcement revenues), the
Company granted TPL the complete and exclusive right to enforce and license
its
microprocessor patent portfolio. The Company then dismissed its patent
infringement claims against Fujitsu Computer Systems, Inc. (“Fujitsu”),
Matsushita Electric Corporation of America (“MEI”), NEC Solutions (America) Inc.
(“NEC”), Sony Electronics Inc. (“Sony”), and Toshiba America Inc., and certain
related entities of these defendants which had been pending in the Federal
District Court for the Northern District of California. Thereafter, TPL, on
behalf of the TPL/Patriot joint venture, filed patent infringement actions
against certain of the foregoing defendants (except Sony) and their related
entities in the Federal District Court for the Eastern District of Texas.
Patriot was subsequently joined as a party to the litigation. Litigation was
not
reinitiated with regard to Fujitsu or NEC and certain of NEC’s subsidiaries as
listed below.
In
February 2006, a license agreement was entered into with Fujitsu regarding
the
Company's patent portfolio, and in connection with that transaction, litigation
involving Fujitsu and TPL and the Company in both California and Texas was
dismissed.
On
August
25, 2006, ARM Ltd. and ARM, Inc. intervened as defendants, seeking a declaration
of non-infringement of our ‘584 patent with respect to ARM processor cores
contained within some alleged infringing chips of other defendants.
In
February 2007, a license agreement was entered into with NEC Corporation, NEC
Corporation of America, Inc., NEC Display Solutions of America, Inc. and NEC
Unified Solutions, Inc. In connection with that transaction, the above named
defendants, excluding NEC Electronics America, Inc., were dismissed from the
lawsuit.
A
Claims
Construction Hearing was held May 3, 2007 in The United States District Court
for the Eastern District of Texas. On June 15, 2007, the court handed down
claims construction of the patents-in-suit, the ‘336, ‘148 and ‘584 patents.
Based on the claims construction ruling, TPL/Patriot proceeded with
discovery with respect to the ‘336 and ‘148 patents. However, based on the
claims construction ruling as to the ‘584 patent claims of “instruction groups”,
TPL/Patriot announced on August 8, 2007, a Stipulation with ARM intended to
expedite an appeal of that claims construction. The Stipulation was a
declaration of non-infringement by the accused ARM products with respect to
the
‘584 patent. A notice of appeal to the Federal Circuit was filed with
respect to the ARM Stipulation and the District Court’s claims construction with
respect to the ‘584 patent.
18
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Commitments
and Contingencies,
continued
On
December 18, 2007 all remaining parties to the litigation announced that a
resolution was reached in the patent infringement lawsuits. The terms
of the settlement included the grant by TPL of rights under the Moore
Microprocessor Patent Portfolio to NEC Electronics America, Toshiba, Matsushita
and JVC and their respective subsidiaries in the form of license
agreements. The parties have agreed that the details of the
settlement are confidential.
401(k)
Plan
We
have a
retirement plan that complies with Section 401(k) of the Internal Revenue Code.
All employees are eligible to participate in the plan. We match 50% of each
participant’s voluntary contributions, subject to a maximum contribution of 6%
of the participant’s compensation. Participants vest 33% per year over a three
year period in our contributions. Our matching contributions during the six
months ended November 30, 2007 and 2006 were $3,388 and $5,607,
respectively.
Employment
Contracts
In
connection with Mr. Turley’s appointment as President and Chief Executive
Officer, and commencing on June 5, 2007, we entered into an employment
agreement with Mr. Turley for a one-year term. Pursuant to the
agreement, if Mr. Turley is terminated without cause, he is entitled to his
then
current salary level for the remaining term of his agreement conditional upon
the execution of a general release.
In
connection with Mr. Flowers’ appointment as the Chief Financial Officer,
and commencing on September 17, 2007, we entered into an employment
agreement with Mr. Flowers for an initial 120-day term if not terminated
pursuant to the agreement, with an extension period of one year and on a
continuing basis thereafter. Pursuant to the agreement, if
Mr. Flowers is terminated without cause or resigns with good reason within
the first two years of employment, he is entitled to receive an amount equal
to
his annual base salary for the greater of (i) 6 months or (ii) the
period remaining in the extended one-year term. If Mr. Flowers
is terminated without cause or resigns with good reason any time after two
years
of continuous employment, he is entitled to receive an amount equal to 12 months
of his annual base salary. Mr. Flowers is also entitled to
certain payments upon a change of control of the Company if the surviving
corporation does not retain him. All such payments are conditional upon the
execution of a general release.
Guarantees
and
Indemnities
We
have
made certain guarantees and indemnities, under which we may be required to
make
payments to a guaranteed or indemnified party. We indemnify our directors,
officers, employees and agents to the maximum extent permitted under the laws
of
the State of Delaware and California for SSDI. In connection with our facility
leases, we have indemnified our lessors for certain claims arising from the
use
of the facilities. The duration of the guarantees and indemnities varies, and
in
many cases is indefinite. These guarantees and indemnities do not provide for
any limitation of the maximum potential future payments we could be obligated
to
make. Historically, we have not been obligated to make any payments for these
obligations and no liabilities have been recorded for these guarantees and
indemnities in the accompanying consolidated balance sheets.
Operating
Leases
We
have a
non-cancelable operating lease agreement for our Carlsbad, California office
facility. Future minimum lease payments required under the operating lease
are
$48,447 and $73,710 in fiscal years ended 2008 and 2009,
respectively.
19
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Commitments
and Contingencies,
continued
SSDI
subleases their Carlsbad, California office facility which was amended to extend
through June 2008 with a month-to-month option until no later than December
2008. Future minimum lease payments required under the operating lease are
$44,324 and $7,351 in fiscal years ended 2008 and 2009,
respectively.
SSDI
also
leases office space in Annapolis, Maryland on a month-to-month basis at $750
per
month expiring February 2008. The lease may be terminated by either party with
30 days notice.
Earn-Out
Agreement
SSDI
entered into an earn-out agreement with a former debt holder of Holocom
Networks, Inc. (“Holocom Networks”) upon our contribution of the foreclosure
sale collateral of Holocom Networks to SSDI in fiscal 2007. The agreement
required the former debt holder to release all of his rights to any Holocom
Networks collateral in exchange for receiving 3% of the net sales (defined
as
cash revenues actually received less credits or discounts and other claims
of
customers) of SSDI’s protected distribution system products for a period of 48
months from the foreclosure sale date of February 2, 2007. The earn-out is
to be
paid each calendar quarter. A liability for payment under this
agreement of $9,032 is included in accrued expenses in the accompanying
condensed consolidated balance sheet at November 30, 2007.
9.
Segment
Information
SSDI
began operations in February 2007 and we consolidated SSDI in our financial
statements in March 2007. SSDI is an operating segment under FASB Statement
No.
131, Disclosures About
Segments of an Enterprise, as revenue is 10% or more of the total revenue
of all operating segments.
SSDI
is
engaged in the business of developing and manufacturing network-security
hardware for sale to government, military, and other high-security facilities.
There is no inter-segment revenue, and the accounting policies for segment
reporting are the same as for us as a whole.
The
“all
other” category includes the results for Patriot Scientific
Corporation.
Operating
segment net revenue, operating loss and income (loss) before taxes for the
three
and six months ended November 30, 2007 and 2006 were as follows:
Three
Months Ended
|
Six
Months Ended
|
|||||||||||||||
November
30, 2007
|
November
30, 2006
|
November
30, 2007
|
November
30, 2006
|
|||||||||||||
Net
revenue:
|
||||||||||||||||
SSDI
|
$ |
933,280
|
$ |
-
|
$ |
1,445,144
|
$ |
-
|
||||||||
All
other
|
12,550
|
18,500
|
22,055
|
44,875
|
||||||||||||
Total
net revenue
|
$ |
945,830
|
$ |
18,500
|
$ |
1,467,199
|
$ |
44,875
|
||||||||
Operating
income (loss):
|
||||||||||||||||
SSDI
|
$ |
120,587
|
$ |
-
|
$ | (25,042 | ) | $ |
-
|
|||||||
All
other
|
(1,906,118 | ) | (8,017,922 | ) | (3,378,845 | ) | (10,724,071 | ) | ||||||||
Total
operating loss
|
$ | (1,785,531 | ) | $ | (8,017,922 | ) | $ | (3,403,887 | ) | $ | (10,724,071 | ) | ||||
Income
(loss) before taxes:
|
||||||||||||||||
SSDI
|
$ |
119,299
|
$ |
-
|
$ |
124,048
|
$ |
-
|
||||||||
All
other
|
3,881,351
|
(1,161,998 | ) |
1,681,647
|
8,328,275
|
|||||||||||
Total
income (loss) before taxes
|
$ |
4,000,650
|
$ | (1,161,998 | ) | $ |
1,805,695
|
$ |
8,328,275
|
20
Patriot
Scientific
Corporation
Notes
to Unaudited Condensed
Consolidated Financial Statements
Segment
Information,
continued
All
sales
were to unaffiliated customers within the United States. During the six months
ended November 30, 2007, one customer accounted for 51% of SSDI’s sales and this
same customer accounted for 27% of SSDI’s accounts receivable at November 30,
2007. Another customer accounted for 17% of SSDI’s sales and this
same customer accounted for 29% of SSDI’s accounts receivable at November 30,
2007.
Operating
segment total assets and depreciation and amortization as of and for the six
months ended November 30, 2007 and 2006 were as follows:
|
2007
|
2006
|
||||||
Depreciation
and amortization:
|
|
|
||||||
SSDI
|
$ |
8,525
|
$ |
-
|
||||
All
other
|
14,390
|
21,288
|
||||||
Total
depreciation and amortization
|
$ |
22,915
|
$ |
21,288
|
|
2007
|
2006
|
||||||
Total
assets:
|
|
|
||||||
SSDI
|
$ |
1,011,498
|
$ |
-
|
||||
All
other
|
21,668,506
|
23,750,911
|
||||||
Total
assets
|
$ |
22,680,004
|
$ |
23,750,911
|
10. Subsequent
Events
On
December 11, 2007 the interest rate on our line of credit with SSDI decreased
to
7.25% in accordance with the change in the prime interest rate.
On
December 18, 2007 we received payment from Phoenix Digital Solutions for the
amount shown as receivable from affiliated company on our November 30, 2007
consolidated balance sheet.
On
December 18, 2007 all remaining parties to the litigation announced that a
resolution was reached in the patent infringement lawsuits. The terms
of the settlement included the grant by TPL of rights under the Moore
Microprocessor Patent Portfolio to NEC Electronics America, Toshiba, Matsushita
and JVC and their respective subsidiaries in the form of license
agreements. The parties have agreed that the details of the
settlement are confidential.
21
Item
2. Management’s Discussion and
Analysis of Financial Condition and Results of Operations
THE
FOLLOWING DISCUSSION INCLUDES FORWARD-LOOKING STATEMENTS WITH RESPECT TO OUR
FUTURE FINANCIAL PERFORMANCE. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE
CURRENTLY ANTICIPATED AND FROM HISTORICAL RESULTS DEPENDING UPON A VARIETY
OF
FACTORS, INCLUDING THOSE DESCRIBED BELOW UNDER THE SUB-HEADING, "RISK FACTORS"
SEE ALSO OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED MAY 31,
2007.
Overview
In
June
2005, we entered into a series of agreements with Technology Properties Limited,
Inc. (“TPL”) and others to facilitate the pursuit of infringers of our
intellectual property. We intend to continue our joint venture with TPL to
pursue license agreements with infringers of our technology. We believe that
utilizing the option of working through TPL, as compared to creating and using
a
Company licensing team for those activities, avoids a competitive devaluation
of
our principal assets and is a prudent way to achieve the desired results as
we
seek to obtain fair value from users of our intellectual property.
During
the fiscal year ended May 31, 2006, we finalized an agreement for the
licensing of our technology with Intel Corporation. During the fiscal years
ended May 31, 2006 and 2007, TPL entered into licensing agreements with
Hewlett-Packard, Fujitsu, Casio, Nikkon, Sony, Seiko Epson, Pentax, Olympus,
Kenwood, Agilent Technologies, Schneider Electric, Lexmark, NEC, Funai Electric,
SanDisk, Sharp and Nokia operating through our joint venture entity, Phoenix
Digital Solutions, LLC (“PDS”). During the six months ended November
30, 2007, TPL entered into licensing agreements with Bull, Lego Systems, DMP
Electronics, Denso Wave, Bossiere (Schneider) and Philips. We believe that
these
agreements represent validation of our position that our intellectual property
was and is being infringed by major manufacturers and users of microprocessor
technology.
Critical
Accounting Policies and
Estimates
Our
condensed consolidated financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America,
which require us to make estimates and judgments that significantly affect
the
reported amounts of assets, liabilities, revenues and expenses, and related
disclosure of contingent assets and liabilities. Actual results could differ
from those estimates, and such differences could affect the results of
operations reported in future periods. We believe the following critical
accounting policies affect our most significant estimates and judgments used
in
the preparation of our condensed consolidated financial statements.
1. Revenue
Recognition
Accounting
for revenue recognition is complex and affected by interpretations of guidance
provided by several sources, including the Financial Accounting Standards Board
(“FASB”) and the Securities and Exchange Commission (“SEC”). This guidance is
subject to change. We follow the guidance established by the SEC in Staff
Accounting Bulletin No. 104, as well as generally accepted criteria for revenue
recognition, which require that, before revenue is recorded, there is persuasive
evidence of an arrangement, the fee is fixed or determinable, collection is
reasonably assured, and delivery to our customer has occurred. Applying these
criteria to certain of our revenue arrangements requires us to carefully analyze
the terms and conditions of our license agreements. Revenue from our technology
license agreements is generally recognized at the time we enter into a contract
and provide our customer with the licensed technology. We believe that this
is
the point at which we have performed all of our obligations under the agreement;
however, this remains a highly interpretive area of accounting and future
license agreements may result in a different method of revenue recognition.
Fees
for maintenance or support of our licenses are recorded on a straight-line
basis
over the underlying period of performance.
Our
consolidated variable interest entity recognizes revenue upon shipment of its
product and recognizes revenue on its short-term installation contracts as
time
and materials costs are incurred.
22
2. Assessment
of Contingent Liabilities
We
are
involved in various legal matters, disputes, and patent infringement claims
which arise in the ordinary course of our business. We accrue for estimated
losses at the time when we can make a reliable estimate of such loss and it
is
probable that it has been incurred. By their very nature, contingencies are
difficult to estimate. We continually evaluate information related to all
contingencies to determine that the basis on which we have recorded our
estimated exposure is appropriate.
3. Stock
Options and Warrants
On
June
1, 2006, we adopted the provisions of SFAS No. 123(R), Share-Based Payment, which
establishes standards for the accounting of transactions in which an entity
exchanges its equity instruments for goods or services, primarily focusing
on
accounting for transactions where an entity obtains employee services in
share-based payment transactions. SFAS No. 123(R) requires a public entity
to measure the cost of employee services received in exchange for an award
of
equity instruments, including stock options, based on the grant-date fair value
of the award and to recognize it as compensation expense over the period the
employee is required to provide service in exchange for the award, usually
the
vesting period. Stock-based awards to non-employees are accounted for
using the fair value method in accordance with SFAS No. 123, Accounting for Stock Based
Compensation.
In
November 2005, FASB issued FASB Staff Position No. FAS 123R-3, “Transition Election Related
to
Accounting for Tax Effects of Share-Based Payment Awards”
(“FAS123R-3”). We have elected to adopt the alternative transition
method provided in FAS 123R-3. The alternative transition method
includes a simplified method to establish the beginning balance of the
additional paid-in capital pool (“APIC pool”) related to the tax effects of
employee share-based compensation, which is available to absorb tax deficiencies
recognized subsequent to the adoption of SFAS No. 123(R).
Stock-based
compensation expense recognized during the period is based on the value of
the
portion of share-based payment awards that is ultimately expected to vest during
the period. Stock-based compensation expense recognized in our condensed
consolidated statement of operations for the six months ended November 30,
2006
included compensation expense for share-based payment awards granted prior
to,
but not yet vested as of May 31, 2006 based on the grant date fair value
estimated in accordance with the pro forma provisions of SFAS No. 123 and
compensation expense for the share-based payment awards granted subsequent
to
May 31, 2006 based on the grant date fair value estimated in accordance
with the provisions of SFAS No. 123(R). Stock-based compensation expense
recognized in our condensed consolidated statement of operations for the six
months ended November 30, 2007 included compensation expense for share-based
payment awards granted subsequent to May 31, 2007 based on the grant date
fair value estimated in accordance with the provisions of SFAS No. 123(R).
As
stock-based compensation expense recognized in the condensed consolidated
statements of operations is based on awards ultimately expected to vest, it
has
been reduced for estimated forfeitures. SFAS No. 123(R) requires forfeitures
to
be estimated at the time of grant and revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates. The estimated average
forfeiture rate for the six months ended November 30, 2007 and 2006, of
approximately 5% was based on historical forfeiture experience and estimated
future employee forfeitures.
Employee
stock-based compensation expense recognized under SFAS No. 123(R) for the
six months ended November 30, 2007 and 2006 was $346,134 and $1,770,000,
respectively, as determined by the Black-Scholes valuation model.
4. Patents
and Trademarks
We
carry
our patents and trademarks at cost less accumulated amortization and we amortize
the patents over their estimated useful lives of four years. We periodically
review the carrying value of the patents and trademarks
for impairment and recognize impairment when the expected future benefit to
be
derived from an individual intangible asset is less than its carrying
value.
23
5. Income
Taxes
We
must
assess the likelihood that we will be able to recover our deferred tax assets.
If recovery is not likely, we must increase our provision for taxes by recording
a valuation allowance against the deferred tax assets that we estimate will
not
ultimately be recoverable. We believe that a substantial majority of the
deferred tax assets recorded on our balance sheet will ultimately be recovered.
However, should there be a change in our ability to recover the deferred tax
assets; the tax provision would increase in the period in which we determined
that the recovery was not probable.
6.
|
Investment
in Affiliated Company
|
We
have a
50% interest in PDS. We account for our investment using the equity method
of
accounting since the investment provides us the ability to exercise significant
influence, but not control, over the investee. Significant influence is
generally deemed to exist if we have an ownership interest in the voting stock
of the investee of between 20% and 50%, although other factors, such as
representation on the investee’s Board of Directors, are considered in
determining whether the equity method of accounting is appropriate. Under the
equity method of accounting, the investment, originally recorded at cost, is
adjusted to recognize our share of net earnings or losses of the investee and
is
recognized in the consolidated statement of operations in the caption “Equity in
earnings of affiliated company”.
We
review
our investment to determine whether events or changes in circumstances indicate
that our carrying amount may not be recoverable. The primary factors we consider
in our determination are the financial condition, operating performance and
near
term prospects of the investee. If a decline in value is deemed to be other
than temporary, we would recognize an impairment loss.
7.
Variable Interest Entity
We
own
100% of the preferred stock of Scripps Secured Data, Inc. (“SSDI”). On March 27,
2007 we entered into an 18 month revolving line of credit with SSDI for a
maximum amount of $500,000. The line of credit caused us to have a variable
interest in SSDI, a variable interest entity, and we have determined that we
are
the primary beneficiary as we absorb more than half of the variable interest
entity’s expected losses. FIN46(R), Consolidation of Variable
Interest
Entities, requires us to consolidate SSDI as long as we are deemed to be
the primary beneficiary.
We
reevaluate our primary beneficiary position at each of our balance sheet dates
using the guidance in FIN46(R). If we are no longer deemed to be the primary
beneficiary of the variable interest entity, we will discontinue
consolidation.
Results
of
Operations
Comparison
of the Six Months Ended
November 30, 2007 and Six Months Ended November 30, 2006.
Our
revenues increased from approximately $45,000 for the six months ended November
30, 2006 to approximately $1,467,000 for the six months ended November 30,
2007.
Our revenue amounts do not include income of approximately $18,745,000 from
our
investment in Phoenix Digital Solutions, LLC for the six months ended November
30, 2006, or income of approximately $4,285,000 from our investment in Phoenix
Digital Solutions, LLC for the six months ended November 30,
2007. During the six months ended November 30, 2007 we recorded sales
amounting to approximately $1,445,000 by our consolidated variable interest
entity, SSDI, with cost of sales amounting to approximately $508,000. During
the
six months ended November 30, 2006 and 2007, we recognized maintenance fee
revenues totaling approximately $12,500 and $12,500 in connection with an
agreement with AMD Corporation during the 2005 fiscal year. The agreement called
for maintenance fees totaling $100,000 connected with a license agreement for
our Ignite technology; the license fee revenue is being recognized as revenue
evenly over the four year period of the license. In addition during the six
months ended November 30, 2007, we recorded sales of approximately $9,600 from
the sale of microprocessor chips that we no longer market. Inventory associated
with the sales of these microprocessor chips is carried at zero
value. During the six months ended November 30, 2006, we recorded
sales of approximately $32,000 relating to the microprocessor
chips.
24
Selling,
general and administrative expenses decreased from approximately $4,469,000
for
the six months ended November 30, 2006 to approximately $3,945,000 for the
six
months ended November 30, 2007. Legal expenses increased by
approximately $63,000 for the six months ended November 30, 2007 compared with
the six months ended November 30, 2006 and accounting expenses decreased by
approximately $228,000 for the six months ended November 30, 2007 compared
with
the six months ended November 30, 2006 the decrease was primarily due to
restatement expenses incurred during the six months ended November 30, 2006.
Salary costs and related expenses included non-cash expenses associated with
the
fair value of options granted during the period in accordance with SFAS No.
123R. During the six months ended November 30, 2007, options were
granted to our newly-appointed chief executive officer and chief financial
officer pursuant to terms of their employment contracts, those option grants
plus the related vesting on the grants resulted in non-cash compensation expense
of approximately $233,000. On August 16, 2007 options were granted to
certain employees and a newly-appointed director resulting in non-cash
compensation of approximately $113,000. During the six months ended
November 30, 2006, 1,500,000 options were granted to our then chief executive
officer resulting in a non-cash compensation expense amounting to approximately
$1,527,000 and options were granted to employees resulting in non-cash
compensation of approximately $184,000. Board of director fees
amounting to approximately $212,000 were paid during the six months ended
November 30, 2007 as compared to $150,000 paid for the six months ended November
30, 2006. Other salary expenses increased by approximately $632,000
for the six months ended November 30, 2007 as compared with the six months
ended
November 30, 2006 including approximately $595,000 in salaries and related
expenses for SSDI during the six months ended November 30, 2007. Salary expenses
for the parent company including wages, payroll taxes, employee benefits and
expenses connected with 401(k) employer matching increased by approximately
$38,000 during the six months ended November 30, 2007 as compared with the
six
months ended November 30, 2006. Travel and related expenses for the
six months ended November 30, 2007 increased by approximately $99,000 due to
expenses for SSDI being combined with the parent company. Consulting
expenses increased by approximately $33,000 for the six months ended November
30, 2007 as compared to the six months ended November 30, 2006 due to one time
fees for evaluations of our various technologies and expenses associated with
our production of materials for the upcoming litigation. Offsetting
the increases in selling, general and administrative expenses for the six months
ended November 30, 2007 as compared to the six months ended November 30, 2006,
were decreases amounting to approximately $85,000 for public relations
expenses.
Settlement
and license expenses amounting to $419,000 were recorded for the six months
ended November 30, 2007 relating to royalties payable resulting from an
agreement with Fish (see Note 4 to our condensed consolidated financial
statements for more information). For the six months ended November
30, 2006, $6,300,000 was recorded related to the Fish agreement.
Our
other
income and expenses for the six months ended November 30, 2007 and 2006 included
equity in the earnings of PDS. The investment is accounted for in accordance
with the equity method of accounting for investments. Our investment in PDS
for
the six months ended November 30, 2007 provided net income after
expenses in the amount of approximately $4,285,000 as compared to net income
after expenses of $18,745,000 for the six months ended November 30, 2006. Total other income and
expense for the six months ended November 30, 2007 amounted to net
other income of approximately $5,210,000 compared with total other income and
expense for the six months ended November 30, 2006 of net other income amounting
to approximately $19,052,000. Interest income and other income increased from
approximately $308,000 for the six months ended November 30, 2006 to
approximately $776,000 for the six months ended November 30, 2007 as interest
bearing account balances increased from cash received as distributions from
our
investment in PDS and we recognized other income of approximately $227,000
in
connection with our reimbursement request billings to PDS for our prior period
legal expenses incurred in connection with the patent
litigation. During the six months ended November 30, 2007, SSDI
recognized $150,000 of other income in connection with the sale of a portion
of
its interest in Holocom MultiDomain Computers, LLC, now known as DataSecurus,
LLC.
25
During
the six months ended November 30, 2006, we recorded a provision for income
taxes
of $4,220,000 related to federal and California taxes. During the six
months ended November 30, 2007, we recorded a provision for income taxes of
approximately $1,351,000 related to federal and California
taxes. Also, during the quarters ended November 30, 2006, and
November 30, 2007, we utilized approximately $34,300,000 and $5,600,000,
respectively, of our available federal net operating loss
carry-forwards. At November 30, 2007 we have utilized all of our
remaining available federal net operating loss
carry-forwards. At May 31, 2007, we had utilized all of our
state net operating loss carry-forwards of approximately
$17,822,000.
We
recorded net income for the six months ended November 30, 2006 of $4,108,275
compared with net income of $454,150 for the six months ended November 30,
2007.
Comparison
of the Three Months Ended
November 30, 2007 and Three Months Ended November 30, 2006.
Our
revenues increased from approximately $19,000 for the three months ended
November 30, 2006 to approximately $946,000 for the three months ended November
30, 2007. Our revenue amounts do not include income of approximately $6,675,000
from our investment in Phoenix Digital Solutions, LLC (“PDS”)for the three
months ended November 30, 2006, or income of approximately $5,486,000 from
our
investment in Phoenix Digital Solutions, LLC for the three months ended November
30, 2007. During the three months ended November 30, 2007 we recorded
sales amounting to approximately $933,000 by our consolidated variable interest
entity, SSDI, with cost of sales amounting to approximately $356,000. During
the
three months ended November 30, 2006 and 2007, we recognized maintenance fee
revenues totaling approximately $6,250 and $6,250 in connection with an
agreement with AMD Corporation during the 2005 fiscal year. The agreement called
for maintenance fees totaling $100,000 connected with a license agreement for
our Ignite technology; the license fee revenue is being recognized as revenue
evenly over the four year period of the license. In addition during the three
months ended November 30, 2007, we recorded sales of approximately $6,300 from
the sale of microprocessor chips that we no longer market. Inventory associated
with the sales of these microprocessor chips is carried at zero
value. During the three months ended November 30, 2006, we recorded
sales of approximately $12,250 relating to the microprocessor
chips.
Selling,
general and administrative expenses increased from approximately $1,736,000
for
the three months ended November 30, 2006 to approximately $1,986,000 for the
three months ended November 30, 2007. Legal expenses increased by
approximately $190,000 for the three months ended November 30, 2007 compared
with the three months ended November 30, 2006 and accounting expenses decreased
by approximately $298,000 for the three months ended November 30, 2007 compared
with the three months ended November 30, 2006. The decrease was
primarily due to restatement expenses incurred during the three months ended
November 30, 2006. Salary costs and related expenses included non-cash expenses
associated with the fair value of options granted during the period in
accordance with SFAS No. 123R. During the three months ended November
30, 2007, options were granted to our newly-appointed chief financial officer
pursuant to terms of his employment contract, those option grants plus the
related vesting on the grants resulted in non-cash compensation expense of
approximately $38,000. During the three months ended November 30,
2006, options were granted to employees resulting in non-cash compensation
of
approximately $184,000. Board of director fees amounting to
approximately $114,000 were paid during the three months ended November 30,
2007
as compared to $90,000 paid for the three months ended November 30,
2006. Other salary expenses increased by approximately $261,000 for
the three months ended November 30, 2007 as compared with the three months
ended
November 30, 2006 including approximately $288,000 in salaries and related
expenses for SSDI during the three months ended November 30, 2007. Salary
expenses for the parent company including wages, payroll taxes, employee
benefits and expenses connected with 401(k) employer matching decreased by
approximately $27,000 during the three months ended November 30, 2007 as
compared with the three months ended November 30, 2006. Travel and
related expenses for the three months ended November 30, 2007 increased by
approximately $56,000, an increase of approximately $9,000 for the parent
company and an increase of $47,000 for SSDI.
26
Settlement
and license expenses amounting to $389,000 were recorded for the three months
ended November 30, 2007 relating to royalties payable resulting from an
agreement with Fish (see Note 4 to our condensed consolidated financial
statements for more information). For the three months ended November
30, 2006, $6,300,000 was recorded related to the Fish agreement.
Our
other
income and expenses for the three months ended November 30, 2007 and 2006
included equity in the earnings of PDS. The investment is accounted for in
accordance with the equity method of accounting for investments. Our investment
in PDS for the three months ended November 30, 2007 provided net
income after expenses in the amount of approximately $5,486,000 as compared
to
net income after expenses of $6,675,000 for the three months ended November
30,
2006. Total other
income and expense for the three months ended November 30, 2007 amounted to
net
other income of approximately $5,786,000 compared with total other income and
expense for the three months ended November 30, 2006 of net other income
amounting to approximately $6,856,000. Interest income and other income
increased from approximately $181,000 for the three months ended November 30,
2006 to approximately $301,000 for the three months ended November 30, 2007
as
interest bearing account balances increased from cash received as distributions
from our investment in PDS.
Liquidity
and Capital
Resources
Liquidity
Our
cash,
marketable securities and short-term investment balances decreased from
approximately $25,955,000 as of May 31, 2007 to approximately $20,206,000 as
of
November 30, 2007. We also have restricted cash balances amounting to
approximately $102,000 as of May 31, 2007 and approximately $50,000 as of
November 30, 2007. Total current assets decreased from approximately $31,399,000
as of May 31, 2007 to approximately $22,559,000 as of November 30, 2007. Total
current liabilities amounted to approximately $2,021,000 and approximately
$6,115,000 as of May 31, 2007 and November 30, 2007, respectively. The change
in
our current position as of November 30, 2007 as compared with May 31, 2007
results in part from our utilization of cash to repurchase warrants and to
purchase treasury stock, which amounted to $5,804,000, while not receiving
cash
distributions from PDS during the three months ended August 31,
2007. Additionally, during the six months ended November 30, 2007, we
utilized our remaining federal net operating losses for income tax purposes,
resulting in a current tax liability of approximately $5,447,000 and causing
our
prepaid income taxes and deferred tax assets at May 31, 2007 to be reclassified
to the current tax liability. Total cash paid for income taxes during
the six months ended November 30, 2007 was $3,958,000. We also used
$500,000 for the settlement of arbitration with a former executive
officer and director of the Company.
Cash
Flows From Operating
Activities
Cash
used
in operating activities for the six months ended November 30, 2007 was
approximately $7,836,000 as compared with cash used in operating activities
for
the six months ended November 30, 2006 of approximately $2,949,000. The
principal components of the current period amount were: net income of
approximately $454,000, change in refundable income taxes of approximately
$2,071,000 and a change in income taxes payable of approximately
$5,447,000. These increases were partially offset by: equity in
earnings of PDS of $4,285,000, change in deferred taxes of approximately
$10,098,000, and changes in accounts payable and accrued expenses of
approximately $1,352,000.
Cash
Flows From Investing
Activities
Cash
used
in investing activities was approximately $408,000 for the six months ended
November 30, 2007 as compared to cash provided by investing activities of
approximately $14,609,000 for the six months ended November 30, 2006. The
decrease was primarily due to a reduction of distributions received from our
investment in affiliate from $15,099,000 in 2006 to $7,738,000 in
2007. Cash used during the six months ended November 30, 2007 also
included $8,281,000 in net purchases of short-term investments and purchases
of
fixed assets of approximately $18,000. The cash used during the six
months ended November 30, 2007 was partially offset by proceeds of $100,000
received by SSDI for the sale of a membership interest in
DataSecurus, LLC and proceeds of $52,500 received from collateral accounts
held
on former officers’ credit cards that were cancelled.
27
Cash
Flows From Financing
Activities
Cash
used
in financing activities for the six months ended November 30, 2007 was
approximately $5,786,000 as compared to approximately $3,927,000 for the six
months ended November 30, 2006 primarily due to payments of approximately
$3,043,000 to repurchase shares of our common stock for treasury and warrant
repurchases of approximately $2,761,000 for the six months ended November 30,
2007. The cash used during the six months ended November 30, 2007 was partially
offset by cash received of approximately $18,000 from the exercise of common
stock options and warrants.
Capital
Resources
Our
current position as of November 30, 2007 is expected to provide the funds
necessary to support our operations through at least the next twelve
months.
Contractual
Obligations and
Committments
A
summary
of our outstanding contractual obligations at November 30, 2007 is as
follows:
Contractual
Cash
Obligations
|
|
Total
Amounts
Committed
|
|
|
1-3
Years
|
|
||
|
|
|
|
|
|
|
||
Operating
leases - facilities
|
|
$
|
176,082
|
|
|
$
|
176,082
|
|
Recent
Accounting
Pronouncements
In
July
2006, the FASB issued Interpretation No. 48, Accounting for Uncertainty
in Income
Taxes - an interpretation of FASB Statement No. 109 (“FIN 48”). This
interpretation clarifies the application of SFAS No. 109, Accounting for Income Taxes,
by defining criteria that an individual tax position must meet for any part
of
the benefit of that position to be recognized in a company’s financial
statements and also provides guidance on measurement, derecognition,
classification, interest and penalties, accounting in interim periods,
disclosure and transition. We adopted FIN 48 on June 1, 2007 and did
not record any cumulative effect adjustment to retained earnings as a result
of
adopting FIN 48. Interest and penalties, if any, related to
unrecognized tax benefits are recorded in income tax expense. As of
June 1, 2007, we are subject to U.S. Federal income tax examinations for the
tax
years May 31, 1991 through May 31, 2007, and we are subject to state and local
income tax examinations for the tax years May 31, 1999 through May 31, 2007
due
to the carryover of net operating losses from prior years.
In
September 2006, the FASB issued SFAS No. 157, Fair Value Measurements
(“SFAS No. 157”). SFAS No. 157 defines fair value, establishes a framework
for measuring fair value in generally accepted accounting principals and expands
disclosures about fair value measurements. The statement does not require
new fair value measurements, but is applied to the extent that other accounting
pronouncements require or permit fair value measurements. The statement
emphasizes that fair value is a market-based measurement that should be
determined based on the assumptions that market participants would use in
pricing an asset or liability. Companies that have assets and liabilities
measured at fair value will be required to disclose information that enables
the
users of its financial statements to access the inputs used to develop those
measurements. The reporting entity is encouraged, but not required, to
combine the fair value information disclosed under this statement with the
fair
value information disclosed under other accounting pronouncements. SFAS
No. 157 is effective for fiscal years beginning after November 15, 2007. We
expect to adopt SFAS No. 157 on June 1, 2008. We are currently assessing
the impact the adoption of SFAS No. 157 will have on our consolidated financial
statements.
28
In
February 2007, the FASB issued SFAS No. 159, The Fair Value Option for
Financial
Assets and Financial Liabilities (“SFAS No. 159”). SFAS No. 159 permits
entities to choose to measure at fair value many financial instruments and
certain other items that are not currently required to be measured at fair
value. The objective is to improve financial reporting by providing entities
with the opportunity to mitigate volatility in reported earnings caused by
measuring related assets and liabilities differently without having to apply
complex hedge accounting provisions. SFAS No. 159 also establishes
presentation and disclosure requirements designed to facilitate comparisons
between entities that choose different measurement attributes for similar types
of assets and liabilities. SFAS No. 159 does not affect any existing
accounting literature that requires certain assets and liabilities to be carried
at fair value. SFAS No. 159 does not establish requirements for
recognizing and measuring dividend income, interest income, or interest expense.
This Statement does not eliminate disclosure requirements included in other
accounting standards. SFAS No. 159 is effective in fiscal years
beginning after November 15, 2007. We are in the process of evaluating the
provisions of the statement, but do not anticipate that the adoption of SFAS
No.
159 will have a material impact on our consolidated financial
statements.
In
December 2007, the FASB issued SFAS No. 141(R), Business Combinations (“SFAS
No. 141(R)”). SFAS No. 141(R) requires acquiring entities in a business
combination to recognize the assets acquired and liabilities assumed in the
transaction; establishes the acquisition-date fair value as the measurement
objective for all assets acquired and liabilities assumed; and requires the
acquirer to disclose to investors the information they need to evaluate and
understand the nature and financial effect of the business combination. SFAS
No. 141(R) is effective in fiscal years beginning after December 15, 2008.
We expect to adopt SFAS No. 141(R) on June 1, 2009. We are currently
assessing the impact the adoption of SFAS No. 141(R) will have on our
consolidated financial statements.
In
December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests
in
Consolidated Financial Statements (“SFAS No. 160”). SFAS No. 160
requires entities to report noncontrolling (minority) interests in subsidiaries
as equity in the consolidated financial statements . SFAS No. 160 is
effective in fiscal years beginning after December 15, 2008. We expect to adopt
SFAS No. 160 on June 1, 2009. We are currently assessing the impact
the adoption of SFAS No. 160 will have on our consolidated financial
statements.
Risk
Factors
We
urge
you to carefully consider the following discussion of risks as well as other
information regarding our common stock. We believe the following to be our
most
significant risk factors as of the date this report is being filed. The risks
and uncertainties described below are not the only ones we face.
We
Have Reported Substantial Income
In 2006 and 2007 Which May Not Be Indicative Of Our Future
Income
During
fiscal 2007 and 2006, we entered into license agreements, directly and through
our joint venture with Technology Properties Limited. Because of the uncertain
nature of the negotiations that lead to license revenues, pending litigation
with companies which we allege have infringed on our patent portfolio, the
possibility of legislative action regarding patent rights, and the possible
effect of new judicial interpretation of patent laws, we cannot predict the
amount of future revenues from such agreements, or whether there will be future
revenues from license agreements at all.
We
Are Dependent Upon A Joint Venture
In Which We Are A Passive Partner For Substantially All Of Our
Income
In
June
of 2005, we entered into a joint venture with Technology Properties Limited,
pursuant to which Technology Properties Limited is responsible for the licensing
and enforcement of our microprocessor patent portfolio. This joint venture
has
been the source of virtually all of our income since June of 2005. Therefore,
in
light of the absence of significant revenue from other sources, we should be
regarded as entirely dependent on the success or failure of the licensing and
prosecution efforts of Technology Properties Limited on behalf of the joint
venture. Sales of our microprocessor products and data security products have
resulted in limited revenues. Our other product lines are no longer being
actively marketed, and also only generate limited and sporadic
sales.
29
Our
Limited Sales And
Marketing Capabilities Have
Affected Our
Revenue
We
currently have limited marketing capabilities and may need to hire additional
sales and marketing personnel. We may not be able to recruit, train, or retain
qualified personnel to sell and market our products. We also may not be able
to
develop a successful sales and marketing strategy. We also have very limited
marketing experience. Any marketing efforts we undertake may not be successful
and may not result in any significant sales of our products.
We
May Experience Difficulties In The
Completion Of Our Development Stage Products
Our
technologies and products are in various stages of development. We do not
currently have in-house development personnel, nor have we retained independent
researchers. Therefore, our development stage products may not be completed
on a
timely basis or at all. Additionally, even if we do recommence our development
activities, our development stage products may not be completed due to the
inherent risks of new product and technology development, limitations on
financing, competition, obsolescence, the absence or loss of key personnel
and
other factors. Although we have licensed some of our technology at its current
stage of development, we may not continue to be able to do so and any revenues
generated from licensing may not be sufficient to support operations at their
current level. Also, unanticipated technical obstacles can arise at any time
and
result in lengthy and costly delays or in a determination that further
development is not feasible.
Changes
In Our Relationships With
Companies In Which We Hold Less Than A Majority Interest Could Change The Way
We
Account For Such Interests In The Future.
We
hold a
minority interest in a company (Scripps Secured Data, Inc.) to which we provide
financing. Under the applicable provisions of accounting principles generally
accepted in the United States of America, including FIN 46(R), we currently
consolidate the financial statements and results of operations of this company
into our consolidated financial statements and results of operations, and record
the equity interest that we do not own as a minority interest. For our other
investment (Phoenix Digital Solutions, LLC), accounted for under the equity
method, we record as part of other income or expense our share of the increase
or decrease in the equity of the company in which we have invested. It is
possible that, in the future, our relationships and/or our interests in or
with
this consolidated entity and equity method investee could change. Such potential
future changes could result in deconsolidation or consolidation of such
entities, as the case may be, which could result in changes in our reported
results.
We
Have Settled A Legal Dispute Which
Could Affect Our Future Results Of Operations And Working Capital
Position
We
were
sued by a co-inventor of the technology underlying our microprocessor patent
portfolio with regard to proceeds we received as a consequence of recently
signed license agreements. On February 14, 2007, we finalized a settlement
of
this litigation. This settlement required us to pay the co-inventor $6,400,000
and requires us to pay up to $2,000,000 from the proceeds we receive from future
licensing transactions. As of the date of this filing, we have paid $1,582,000
of the $2,000,000 obligation for future licensing transaction proceeds required
under the settlement agreement. These payments have resulted, and will result,
in a reduction of our net income in the current fiscal year and future quarters
until our obligations under the settlement have been fulfilled.
30
A
Successful Challenge To Our
Intellectual Property Rights Would Have A Significant And Adverse Effect On
Us
A
successful challenge to our ownership of our technology or the proprietary
nature of our intellectual property would materially damage our business
prospects. We rely on a combination of patents, trademarks, copyrights, trade
secret laws, confidentiality procedures and licensing arrangements to protect
our intellectual property rights. We currently have seven U.S. patents, one
European patent, and one Japanese patent issued. Any issued patent may be
challenged and invalidated. Patents may not be issued for any of our pending
applications. Any claims allowed from existing or pending patents may not be
of
sufficient scope or strength to provide significant protection for our products.
Patents may not be issued in all countries where our products can be sold so
as
to provide meaningful protection or any commercial advantage to us. Our
competitors may also be able to design around our patents.
Vigorous
protection and pursuit of intellectual property rights or positions characterize
the fiercely competitive semiconductor industry, which has resulted in
significant and often protracted and expensive litigation. Therefore, our
competitors and others may assert that our technologies or products infringe
on
their patents or proprietary rights. Persons we believe are infringing our
patents are likely to vigorously defend their actions and assert that our
patents are invalid. Problems with patents or other rights could increase the
cost of our products or delay or preclude new product development and
commercialization by us, and limit future license revenue. If infringement
claims against us are deemed valid or if our infringement claims are
successfully opposed, we may not be able to obtain appropriate licenses on
acceptable terms or at all. Litigation could be costly and time-consuming but
may be necessary to protect our future patent and/or technology license
positions or to defend against infringement claims. Parties have
petitioned the U. S. Patent and Trademark Office to re-examine certain of our
patents. An adverse decision in litigation or in the re-examination process
would have a very significant and adverse effect on our business.
On
December 18, 2007 we announced that a resolution was reached in two patent
infringement lawsuits in the U.S. District Courts in the Eastern District of
Texas and the Northern District of California. There are no
assurances that the resolution will favorably impact, or that it will not
impair, our ability to assert our technology rights in the future.
If
A Large Number Of Our Shares Are
Sold All At Once Or In Blocks, The Market Price Of Our Shares Would
Most Likely
Decline
Our
warrant holders are not restricted in the price at which they can sell common
stock acquired through the exercise of warrants. Shares sold at a price below
the current market price at which the common stock is trading may cause the
market price to decline.
The
Market For Our Stock Is Subject
To Rules Relating To Low-Priced Stock (“Penny Stock”) Which May Limit Our
Ability To Raise Capital
Our
common stock is currently listed for trading in the National Association of
Securities Dealers (“NASD”) Over-The-Counter Bulletin (“OTC”) Board Market and
is subject to the “penny stock rules” adopted pursuant to Section 15(g) of the
Exchange Act. In general, the penny stock rules apply to non-NASDAQ or
non-national stock exchange companies whose common stock trades at less than
$5.00 per share or which have tangible net worth of less than $5,000,000
($2,000,000 if the company has been operating for three or more years). Such
rules require, among other things, that brokers who trade “penny stock” on
behalf of persons other than “established customers” complete certain
documentation, make suitability inquiries of investors and provide investors
with certain information concerning trading in the security, including a risk
disclosure document, quote information, broker’s commission information and
rights and remedies available to investors in penny stocks. Many brokers have
decided not to trade “penny stock” because of the requirements of the penny
stock rules, and as a result, the number of broker-dealers willing to act as
market makers in such securities is limited. The “penny stock rules,” therefore,
may have an adverse impact on the market for our common stock and may affect
our
ability to raise additional capital if we decide to do so.
31
Our
Share Price Could Decline As A
Result Of Short Sales
When
an
investor sells stock that he does not own, it is known as a short sale. The
seller, anticipating that the price of the stock will go down, intends to buy
stock to cover his sale at a later date. If the price of the stock goes down,
the seller will profit to the extent of the difference between the price at
which he originally sold it less his later purchase price. Short sales enable
the seller to profit in a down market. Short sales could place significant
downward pressure on the price of our common stock. Penny stocks which do not
trade on an exchange, such as our common stock, are particularly susceptible
to
short sales.
Our
Future Success Depends In
Significant Part Upon The Continued Services Of Our Key Senior
Management
Our
future success depends in significant part upon the continued services of our
key senior management personnel. The competition for highly qualified personnel
is intense, and we may not be able to retain our key managerial employees or
attract and retain additional highly qualified technical and managerial
personnel in the future. None of our employees are represented by a labor union,
and we consider our relations with our employees to be good. None of our
employees are covered by key man life insurance policies.
Item
3. Quantitative and Qualitative
Disclosures About Market Risk
Our
exposure to market risk for changes in interest rates relates primarily to
our
short-term investments. At November 30, 2007 approximately $7.5
million of our short-term investment balance consisted of
auction rate securities. The auction rate securities are
adjustable-rate securities with interest rates that are reset periodically
by
bidders through Dutch auctions generally conducted every 7 to 90 days by a
trust
company or broker/dealer on behalf of the issuer. We believe these
securities are highly liquid investments through the related auctions; however,
the collateralizing securities have long-term maturities. All of our
auction rate securities are rated AAA by Moody’s, Fitch and S & P
ratings. Our short-term investments are intended to establish a
high-quality portfolio that preserves principal, meets liquidity needs, avoids
inappropriate concentrations and delivers an appropriate yield in relationship
to our investment guidelines.
Item
4. Controls and
Procedures
Evaluation
of Disclosure Controls
and Procedures
As
required by Rule 13a-15(e) under the Exchange Act, as of November 30,
2007, the end of the period to which this quarterly report relates, we have
carried out an evaluation of the effectiveness of the design and operation
of
our disclosure controls and procedures. This evaluation was carried
out under the supervision and with the participation of our management,
including our Chief Executive Officer and our Chief Financial
Officer.
Disclosure
controls and procedures are controls and other procedures that are designed
to
ensure that information required to be disclosed in our report filed or
submitted under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified in the Securities and Exchange
Commission’s rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that
information required to be disclosed in our reports filed under the Exchange
Act
is accumulated and communicated to management, including the Chief Executive
Officer and Chief Financial Officer as appropriate, to allow timely decisions
regarding required disclosure. Management recognizes that any controls and
procedures, no matter how well designed and operated, can provide only
reasonable assurance of achieving their objectives, and management necessarily
applies its judgment in evaluating the cost-benefit relationship of possible
controls and procedures. Based on the evaluation of our disclosure
controls and procedures as of November 30, 2007, our Chief Executive
Officer and Chief Financial Officer concluded that, as of such date, our
disclosure controls and procedures were effective.
32
Changes
in Internal Control over
Financial Reporting
There
were no changes to our internal control over financial reporting (as defined
in
Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most
recently completed fiscal quarter that materially affected, or are reasonably
likely to materially affect, our internal control over financial
reporting.
PART
II- OTHER
INFORMATION
Item
1. Legal
Proceedings
On
December 18, 2007 all remaining parties to the litigation announced that a
resolution was reached in the patent infringement lawsuits. The terms
of the settlement included the grant by TPL of rights under the Moore
Microprocessor Patent Portfolio to NEC Electronics America, Toshiba, Matsushita
and JVC and their respective subsidiaries in the form of license
agreements. The parties have agreed that the details of the
settlement are confidential.
The
Company had been in arbitration with Lowell Giffhorn, a former executive
officer and a former director of the Company over matters related to the
termination of Mr. Giffhorn's employment with the
Company. On November 1, 2007, the Company and Mr. Giffhorn
reached a settlement where Mr. Giffhorn was given $500,000 and 200,000 shares
of
restricted Company stock in exchange for a comprehensive release of all claims
against the Company.
Item
1A. Risk
Factors
No
material changes from the risk factors contained in our 10-K for the year ended
May 31, 2007. Please see Part I, Item 2, above, for our risk
factors.
Item
2. Unregistered Sales of Equity
Securities and Use of Proceeds
On
April
28, 2006, our Board of Directors authorized a stock repurchase
program. We commenced the program in July 2006 and plan to repurchase
outstanding shares of our common stock on the open market from time to
time. As part of the program, we purchased 737,181 shares of our
common stock at an aggregate cost of $317,128 during the three months ended
November 30, 2007.
Following
is a summary of all repurchases by the Company of its common stock during the
three month period ended November 30, 2007:
Period
|
Total
Number
of Shares
Purchased
|
Average
Price Paid per
Share
|
Total
Number of Shares
Purchased as Part of Publicly Announced Plans or
Programs
|
|||
September
1 – 30, 2007
|
368,960
|
$ |
0.40
|
368,960
|
||
October
1 – 31, 2007
|
368,221
|
$ |
0.46
|
368,221
|
||
November
1 – 30, 2007
|
-
|
$ |
-
|
-
|
||
Total
|
737,181
|
$ |
0.43
|
737,181
|
On
November 5, 2007 we issued 200,000 shares of our common stock to a former
officer in connection with a legal settlement.
Item
3. Defaults Upon Senior
Securities
None.
33
Item
4. Submission of Matters to a
Vote of Security Holders
At
our
fiscal 2007 Annual Meeting of Shareholders held on October 23, 2007, the
following individuals were elected to the Board of Directors of the Company:
David H. Pohl, Carlton M. Johnson, Jr., Helmut Falk, Jr., Gloria H. Felcyn,
James L. Turley, and Harry L. Tredennick.
The
following proposals were approved at our Annual Meeting of
Shareholders:
1.
|
Proposal
to ratify management’s selection of KMJ Corbin & Company LLP as
the Company’s independent auditors:
|
Votes
For
|
|
Votes
Against
|
|
Votes
Abstaining
|
299,939,156
|
|
2,296,488
|
|
8,814,305
|
2.
|
Election
of Directors:
|
Director
|
|
Votes
For
|
|
Votes
Abstaining
and/or
Against
|
David
H. Pohl
|
|
292,817,894
|
|
18,232,056
|
Carlton
M. Johnson, Jr.
|
|
291,285,030
|
|
19,764,920
|
Helmut
Falk, Jr.
|
|
292,352,425
|
|
18,697,525
|
Gloria
H. Felcyn
|
|
292,268,984
|
|
18,780,966
|
James
L. Turley
|
|
300,843,675
|
|
10,206,275
|
Harry
L. Tredennick
|
300,916,854
|
10,133,096
|
Item
5. Other
Information
None.
Item
6. Exhibits
Those
exhibits marked with an asterisk (*) refer to exhibits filed herewith. The
other
exhibits are incorporated herein by reference, as indicated in the following
list.
Exhibit No.
|
Document
|
2.1
|
Agreement
to Exchange Technology for Stock in the Company, incorporated by
reference
to Exhibit 2.1 to Form 8-K dated August 10, 1989 (Commission
file No. 33-23143-FW)
|
2.2
|
Assets
Purchase Agreement and Plan of Reorganization dated June 22, 1994,
among the Company, nanoTronics Corporation and Helmut Falk, incorporated
by reference to Exhibit 10.4 to Form 8-K dated July 6, 1994
(Commission file No. 000-22182)
|
2.2.1
|
Amendment
to Development Agreement dated April 23, 1996 between the Company and
Sierra Systems, incorporated by reference to Exhibit 2.2.1 to
Pre-Effective Amendment No. 1 to Registration Statement on Form SB-2
filed April 29, 1996 (Commission file No. 333-01765)
|
34
2.3
|
Form
of Exchange Offer dated December 4, 1996 between the Company and
certain shareholders of Metacomp, Inc., incorporated by reference
to
Exhibit 2.3 to Form 8-K filed January 9, 1997 (Commission file
No. 000-22182)
|
|
2.4
|
Letter
of Transmittal to Accompany Shares of Common Stock of Metacomp, Inc.
Tendered Pursuant to the Exchange Offer Dated December 4, 1996,
incorporated by reference to Exhibit 2.4 to Form 8-K filed
January 9, 1997 (Commission file No. 000-22182)
|
|
3.1
|
Original
Articles of incorporation of the Company’s predecessor, Patriot
Financial Corporation, incorporated by reference to Exhibit 3.1 to
registration statement on Form S-18, (Commission file No.
33-23143-FW)
|
|
3.2
|
Articles of
Amendment of Patriot Financial Corporation, as filed with the Colorado
Secretary of State on July 21, 1988, incorporated by reference to
Exhibit 3.2 to registration statement on Form S-18, (Commission file
No. 33-23143-FW)
|
|
3.3
|
Certificate
of Incorporation of the Company, as filed with the Delaware Secretary
of
State on March 24, 1992, incorporated by reference to
Exhibit 3.3 to Form 8-K dated May 12, 1992 (Commission file No.
33-23143-FW)
|
|
3.3.1
|
Certificate
of Amendment to the Certificate of Incorporation of the Company,
as filed
with the Delaware Secretary of State on April 18, 1995, incorporated
by reference to Exhibit 3.3.1 to Form 10-KSB for the fiscal year
ended May 31, 1995 (Commission file No. 000-22182)
|
|
3.3.2
|
Certificate
of Amendment to the Certificate of Incorporation of the Company,
as filed
with the Delaware Secretary of State on June 24, 1997, incorporated
by reference to Exhibit 3.3.2 to Form 10-KSB for the fiscal year
ended May 31, 1997, filed July 18, 1997 (Commission file No.
000-22182)
|
|
3.3.3
|
Certificate
of Amendment to the Certificate of Incorporation of the Company,
as filed with the Delaware Secretary of State on April 28, 2000,
incorporated by reference to Exhibit 3.3.3 to Registration Statement
on Form S-3 filed May 5, 2000 (Commission file No.
333-36418)
|
|
3.3.4
|
Certificate
of Amendment to the Certificate of Incorporation of the Company,
as filed
with the Delaware Secretary of State on May 6, 2002, incorporated by
reference to Exhibit 3.3.4 to Registration Statement on Form S-3
filed June 27, 2002 (Commission file No. 333-91352)
|
|
3.3.5
|
Certificate
of Amendment to the Certificate of Incorporation of the Company,
as filed
with the Delaware Secretary of State on October 16, 2003,
incorporated by reference to Exhibit 3.3.5 to Registration Statement
on Form SB-2 filed May 21, 2004 (Commission file No.
333-115752)
|
|
3.4
|
Articles and
Certificate of Merger of Patriot Financial Corporation into the Company
dated May 1, 1992, with Agreement and Plan of Merger
attached thereto
as Exhibit A, incorporated by reference to Exhibit 3.4 to Form
8-K dated May 12, 1992 (Commission file No. 33-23143-FW)
|
|
3.5
|
Certificate
of Merger issued by the Delaware Secretary of State on May 8, 1992,
incorporated by reference to Exhibit 3.5 to Form 8-K
dated
May 12, 1992 (Commission file No.
33-23143-FW)
|
35
3.6
|
Certificate
of Merger issued by the Colorado Secretary of State on May 12, 1992,
incorporated by reference to Exhibit 3.6 to Form 8-K dated
May 12, 1992 (Commission file No. 33-23143-FW)
|
3.7
|
Bylaws
of the Company, incorporated by reference to Exhibit 3.7 to Form 8-K
dated May 12, 1992 (Commission file No. 33-23143-FW)
|
4.1
|
Specimen
common stock certificate, incorporated by reference to Exhibit 4.1
Form 8-K dated May 12, 1992 (Commission file No.
33-23143-FW)
|
4.2
|
1996
Stock Option Plan of the Company dated March 25, 1996 and approved by
the Shareholders on May 17, 1996, incorporated by reference to
Exhibit 10.13 to Pre-Effective Amendment No. 2 to Registration
Statement on Form SB-2 filed May 23, 1996 (Commission file No.
333-01765)
|
4.3
|
2001
Stock Option Plan of the Company dated February 21, 2001 incorporated
by reference to Exhibit 4.19 to Registration Statement on Form S-8
filed March 26, 2001 (Commission file No. 333-57602)
|
4.4
|
2003
Stock Option Plan of the Company dated July 2, 2003 incorporated by
reference to Exhibit 4.27 to Registration Statement on Form S-8 filed
September 4, 2003 (Commission file No. 333-108489)
|
4.5
|
2006
Stock Option Plan of the Company dated March 31, 2006 incorporated by
reference to Exhibit 4.19 to Registration Statement on Form S-8 filed
June 20, 2006 (Commission file No. 333-135156)
|
4.6
|
Approval
Rights Agreement and Termination of Antidilution Agreement and Addendum
to
Warrants dated October 10, 2006, incorporated by reference to
Exhibit 4.29 to Form 10-KSB for the fiscal year ended May 31,
2006, filed on October 13, 2006 (Commission file No.
000-22182)
|
10.1
|
Employment
Agreement dated June 5, 2007 by and between the Company and James
Turley,
incorporated by reference to Exhibit 10.1 to Form 8-K filed June
8, 2007
(Commission file No. 000-22182)
|
10.2
|
Employment
Agreement dated September 17, 2007 by and between the Company and
Clifford
Flowers, incorporated by reference to Exhibit 10.1 to Form 8-K filed
September 19, 2007 (Commission file No. 000-22182)
|
31.1*
|
Certification
of James L. Turley, CEO, pursuant to Rule
13a–14(a)/15d–14(a)
|
31.2*
|
Certification
of Clifford L. Flowers, CFO, pursuant to Rule
13a–14(a)/15d–14(a)
|
32.1*
|
Certification
of James L. Turley, CEO, pursuant to Section 1350 of Chapter 63 of
Title 18 of the United States Code
|
32.2*
|
Certification
of Clifford L. Flowers, CFO, pursuant to Section 1350 of Chapter
63 of
Title 18 of the United States
Code
|
36
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
DATED: January 9,
2008
|
PATRIOT
SCIENTIFIC CORPORATION
/S/
JAMES L.
TURLEY
James
L. Turley
Chief
Executive Officer
|
In
accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on
the
dates indicated.
Signature
|
Title
|
Date
|
/S/
JAMES L.
TURLEY
James
L. Turley
|
President,
Chief Executive Officer, and Director
|
January
9, 2008
|
/S/
CLIFFORD L.
FLOWERS
Clifford
L. Flowers
|
Chief
Financial Officer and Principal Accounting Officer
|
January 9,
2008
|
/S/
DAVID H.
POHL
David
H. Pohl
|
Chairman
|
January 9,
2008
|
/S/
CARLTON M.
JOHNSON
Carlton
M. Johnson
|
Director
|
January 9,
2008
|
/S/
GLORIA H.
FELCYN
Gloria
H. Felcyn
|
Director
|
January 9,
2008
|
/S/
HELMUT FALK,
JR.
Helmut
Falk, Jr.
|
Director
|
January 9,
2008
|
/S/
HARRY L.
TREDENNICK
Harry
L. Tredennick
|
Director
|
January 9,
2008
|
37